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Cancer is one of the leading causes of human mortality and mortality in all 
diseases. There has been a boost in developing nanocarrier-based therapies for 
treating cancer or other diseases during the past decade. One of the major 
advantages about nanocarrier (with the size range from 1-1000 nm) lies in its 
ability to specifically target tumor and maximize drug accumulation in tumor foci 
through the enhanced permeability and retention effect. Advancement in 
nanotechnology has opened a new paradigm in pharmaceutical field. But new 
challenges have to be overcome in order to fully exploit the technology and 
improve safety in clinical application.  
To improve their performance, at least two types of multifunctional 
nanocarriers are being developed in our lab. The first type of nanocarrier is glycol 
chitosan based polymer delivery system, which is a one-step preparation system, 
with excellent loading capacity. We can use the nanocarrier to guide its loading 
cargo such as anticancer agents to release in a particular subcellular location, or 
to load multiple drugs together to increase therapeutic efficacy. The other system 
is a gold nanoparticle gated mesoporous silica hybrid system, by which we are 
able to simultaneously execute multiple anticancer therapies such as the 
combination of photothermal therapy and chemotherapy. Compared with the first 
generation of nano-delivery system, our new nanocarrier enters cells more 
efficiently through sigma 2 receptors. Moreover, it can serve as a diagnostic tool 
vi 
 
through PET (Positron emission tomography), and our study shows that it is able 
to detect all the spontaneously lung tumors. We believe that these multifunctional 
nanocarriers have the potential benefits in various areas of current 




 Cancer is among the leading causes of human morbidity and mortality of 
all the diseases worldwide. Three prevalent cancers among males are prostate 
cancer, colorectal cancer and melanoma, and in females they are breast cancer, 
uterine corpus and colon and rectum.1 Although during the past decades a 
significant improvement has been made in extending patients’ life or even curing 
some patients by chemotherapy, radiation or surgery, more efforts are still 
required to fight against this life threating disease. For all the subtypes of 
metastatic breast cancer and advanced pancreatic cancer, cytotoxic 
chemotherapy is still the fundamental strategy.2 However, the traditional 
chemotherapeutic effect is often hampered by its side effects towards some 
important organs. For example, doxorubicin is a highly potent anticancer drug 
used to treat solid and hematopoietic tumors, but it can cause acute cardiac 
injury and chronic heart failure.3 One of the common toxic effect associated with 
fluorouracil, oxaliplatin and irinotecan is hepatic steatosis with the frequency over 
20%,4 and for methotrexate, cytarabine and ifosfamide they are well known for 
central neurotoxic side effects.5 Besides of these side effects, the poor 
pharmacokinetic parameters of some chemotherapeutical agents request for a 
frequent dose and often have insufficient bioavailability in tumor. Moreover, we 
are facing the complicating issues of cancer. No matter what kind of cancer or at 
which stage of cancer, there are constant needs for building up a personalized
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therapy that has higher efficacy and less side effects. Therefore, a more 
advanced and systemic therapy is unmet need. 
There has been a boost in developing nanocarrier-based therapies for 
treating cancer or other diseases during the past decade. One of the major 
advantages about nanocarrier lies in its selectivity in tumor foci through the 
enhanced permeability and retention effect (EPR, nanoparticles can 
accumulation tumor tissue through the highly porous vasculature structure of 
newly born tumor vessels and ineffective lymphatic drainage system).6 The first 
generation of nanoformulation that enters the clinical can be categorized as 
liposome, PEGylated proteins, nanocrystals, protein-drug conjugates as well as 
polymer-based nanoparticles.7 The representative examples include Abraxane 
(albumin-bound nanoparticles) for treating metastatic breast cancer,8 Doxil 
(Doxorubicin liposome) for treating Kaposi sarcoma,9 and Zinostatin stimalamer 
(polymer drug conjugates) for treating hepatocellular carcinoma. Advancement in 
nanotechnology has opened a new paradigm in pharmaceutical field. But more 
challenges have to be overcome in order to fully take advantage of this 
nanotechnology and push it to broader clinical applications. To improve their 
performance, various multifunctional nanocarriers are being developed by many 
groups. By infusing the original system with higher targeting efficacy, the function 
of diagnosis, higher drug-loading capacity and versatile drug-loading flexibility, 
the newer generation of nanocarries tends to be more efficient and practical in 
the era of personalized medicine.  
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With the goal above, three strategies have been developed and applied to 
improve the function of nanocarries in our thesis research. The first strategy is to 
functionalize the original polymer nanoparticles for selective intracellular delivery 
of drugs, which minimizes the off-target side effects. Because of specific 
environmental parameters, different subcellular compartments can be selectively 
targeted by specialized nanoparticles. For example, owing to the fact that 
lysosomes (pH range 4.5-5)10 and cytosol and mitochondria have higher reducing 
environment, different stimuli-responsive nanoparticles made from polymers or 
metal particles have been designed and synthesized.11 Disulfide bond, selenium 
or ferrocene and borate ester containing system were among the most popular 
oxidation-responsive systems for the intracellular delivery. Here, we developed 
an environment-sensitive peptide delivery system, dual secured nano-sting 
(DSNS), through the combination of a zwitterionic glycol chitosan and disulfide 
bonds. It released drug only if it went through an environment that had both 
acidic and reducing conditions. 
The second strategy we utilized is to create multifunctional nanocarriers 
capable of diagnosis, therapy and therapeutic outcomes monitoring. Previous 
study showed that “theranostic particles”, with their unique optical properties, can 
either carry imaging molecules or acted as the imaging agent.12 In our study, we 
fabricated gold nanosphere/mesoporous silica hybrid (GoMe) nanocarriers to 
encapsulate either a hydrophilic drug, doxorubicin, or a hydrophobic sensitizer, 
Pc 4. In the animal model study, the former nanocarrier not only showed the 
potential of providing a combined chemotherapy and photothermal (PTT) therapy 
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for cancer, but also demonstrated the ability of diagnosing lung cancer when 
radioactive copper was incorporated; by combining PTT and photodynamic 
therapy (PDT), the latter nanocarrier is able to kill cancer cells and eradicate 
head and neck cancer. 
The third strategy we utilized is to generate multifunctional nanocarries 
with the capacity of co-delivering of different drugs. One of major advantages for 
co-deliver drugs is their suppression of the notorious chermoresistance and 
metastasis.13 It is of particularly importance when a systemic chemotherapy is 
required for patients with middle- to late-stage of metastatic cancers. The classic 
example is to co-deliver anti-metastasis and chemotherapeutic agents, where 
angiogenesis inhibitor can normalize the tumor vasculature and potentiate the 
co-delivered chemotherapeutic drugs.14 Especially at the low-dose of 
antiangiogenic/metronomic chemotherapy, this combination can achieve 
comparable efficacy but much less side effects and drug resistance.15 In the last 
part of this project, we succeeded to combine the suramin, an inhibitor of VEGF 
(vascular endothelial growth factor) and bFGF (basic fibroblast growth factor), 
with doxorubicin in a bio-compatible polymer-based system, which partially 
utilized suramin as the constructing networks and showed that the new 
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Dual secured nano-melittin for safe and effective eradicating cancer cells1 
ABSTRACT 
Clinical application of natural and synthetic amphipathic peptides (e.g., 
melittin) for cancer therapy is hindered by their notorious side effect, lysing red 
blood cells. To safely deliver a therapeutic peptide to the tumor tissue and kill 
cancer cells, we developed an environment-sensitive peptide delivery system, 
dual secured nano-sting (DSNS), through the combination of a zwitterionic glycol 
chitosan and disulfide bonds. Melittin loaded DSNS could kill almost 100% of 
MCF-7, HCT-116, SKOV-3, and NCI/ADR-RES (multidrug resistant) cancer cells 
at the concentration of 5 µM, while not showing hemolytic effect. 
INTRODUCTION 
The host defense amphipathic peptides found in eukaryotic cells have 
diverse activities in human and other species originating from their antibiotic, 
anticancer and anti-inflammatory activities.16 These peptides oligomerize with 
phospholipids in cell membrane, result in pore formation, and subsequently 
cause cell death. Additionally, they act in a similar way on the membranes of 




Amphipathic peptides have been explored for cancer chemotherapy 
because of their wide-spectrum lytic properties. Melittin is one of the most 
promising amphipathic water-soluble α-helical cationic polypeptide and is derived 
from toxin of honey bee Apis melllifera.18 Melittin partitions into and moves 
laterally in the cell membranes as monomers, followed by oligomerization into 
toroidal structures, forming pores which results in cell death.18-19 Furthermore, 
most recent research showed that melittin can induce cancer cell apoptosis 
through the inhibition of JAK2/STAT3 pathway.20 It is worth mentioning that 
melittin also suppresses the constitutively activated NF-κB, which is partially 
responsible for the development of drug resistance in cancer cells.21 It is a very 
attractive cancer therapeutic agent, because cancer cells are less likely to 
develop resistance to cytolytic peptides.19a, 22 
Despite all of these advantages, its non-specific cytolytic activity could 
lead to off-target effects such as hemolysis (lysis of red blood cells) when 
administrated intravenously. Besides that, positively charged peptide could be 
cleared from blood circulation rapidly by the reticuloendothelial system (RES) 
system.23 Several groups developed melittin delivery systems either by 
covalently fusing melittin with receptor-targeted peptide motifs or through 
physically encapsulating it into liposomes or polymer nanoparticles to attenuate 
its hemolytic effect while achieving therapeutic efficiency comparable to free 
melittin.24 Compared with free melittin, their anticancer efficacies were 
significantly decreased for the encapsulated form. Until recently, Soman et al. 




promising results in inhibiting the growth of melanoma tumors.25 Despite the 
encouraging outcome of “nanobee”, they also found that “nanobee” was about 
five-fold less effective as that of melittin for the tested cancer cells. 
An ideal melittin carrier should be able to completely quench its hemolytic 
activity while fully retaining its advantages, including wide spectrum and potent 
anticancer activities. To solve this dilemma, we rationally designed a melittin 
delivery system by integrating a zwitterionic glycol chitosan and disulfide bonds. 
Due to its zwitterionic property, succinic anhydride modified glycol chitosan (SA-
GCS) shows negative surface charges at physiological pH. Positively charged 
melittin can form complexes with SA-GCS through the electrostatic effect. The 
complex will be further stabilized through disulfide crosslinking to yield dual 
secured nano-sting (DSNS) by aerial oxidation (Figure 1.1A).  
RESULTS 
Functionalization of zwitterionic glycol chitosan 
The zwitterionic glycol chitosan was synthesized from glycol chitosan by 
acetylation with succinic anhydride. First, glycol chitosan was depolymerized by 
potassium persulfate according to the literature and purified by dialysis against DI 
water.26 The molecular weight or the deacetylation degree of commercial glycol 
chitosan purchased from Sigma-Aldrich wasn’t strictly controlled. By 
depolymerization, we were able to minimize the batch to batch difference on 
molecular weight, solubility and cytotoxicity of GCS. Glycol chitosan was 
depolymerized by free radical degradation with thermal dissociation initiator 




during depolymerization. The resultant molecular weights of GCS was depend on 
the degradation time, a 0.5 h reduction time led to a final molecular weight of 40 
kDa, and the longest degradation time (t=24 h) resulted in a 10 kDa molecular 
weight. Taking into account of the advantages of solubility, cytotoxicity and 
binding affinity, the resulting polymer was depolymerized for 2 h and achieved a 
molecular weight of 28 kDa and PDI of 1.38 (Figure 1.2). After that, glycol 
chitosan was modified according to our previously published method with 
succinic anhydride (Figure 1.3).23, 27 SA-GCS showed negative surface charge at 
pH 7.4, and positive surface charge at pH below its isoelectric point (IEP) (Figure 
1.4B). Furthermore, the IEP of the modified glycol chitosan can be tuned by 
adjusting the feeding ratio of succinic anhydride and glycol chitosan. To introduce 
free thiol groups, SA-GCS was reacted with N-succinimidyl 3-[2-pyridyldithio]-
propionate (SPDP) and subsequently cleaved with tris(2-carboxyethyl)phosphine 
(TCEP) to achieve thiolated modified glycol chitosan (SA-GCS-SH) (Figure 1.1B, 
1.4A). DTNB reacted with thiol groups in GCS and generated TNB product which 
was detectable at 412 nm. DTNB assay showed that each polymer chain 
contains 8.7 free SH groups. The IEP of the SA-GCS slightly decreased after the 
thiolation (Figure 1.4B).  
To verify that zwitterionic glycol chitosan can form complexes with 
positively charged melittin, we fabricated the single secure nano-sting (SSNS) by 
mixing SA-GCS with melittin at pH 7.4 for 2 h at room temperature. The binding 
efficiency for SA-GCS was determined by measuring the fluorescence intensity 




measurement showed that with the increase of SA-GCS polymer, the detectable 
free melittin gradually decreases and achieved 100% encapsulation at the 
polymer to melittin ratio (W/W) of 40 (Figure 1.5). 
To further stabilize the complex, inhibit its premature release of melittin, 
and eliminate its potential side effects, we substituted the SA-GCS with SC-GCS-
SH and aerially oxidized the complex to promote the formation of disulfide bond 
among the SA-GCS-SH polymers to achieve so called dual secured nano-sting 
(DSNS). Since safety is an essential requirement for melittin related delivery, 
polymer to melittin ratio (W/W) of 200 was selected to ensure that no free melittin 
was remaining after the formation of the complexes. The formation of DSNS was 
confirmed by dynamic light scattering (DLS) (Figure 1.6) and transmission 
electron microscopy (TEM) (Figure 1.7). The hydrodynamic size of SSNS (220.2 
nm, PDI: 0.191) was slightly increased to 223.4 nm after oxidation (PDI: 0.161). 
The size determined by DLS was larger than that obtained by TEM. This is 
because TEM measured the size of solid particles while DLS measured the 
hydrodynamic size of particles which includes the hydration shell surrounding a 
particle. This slight size difference between SSNS and DSNS reflected the size 
decrease and increase due to the formation of intra-particle and inter-particle 
crosslinking, respectively. Surface charge of the both nano-complexes at pH 7.4 
was slightly negative (Figure 1.8), which will help the nano-complexes escape 
from the detecting of reticuloendothelial system and take advantage of the 




confirmed that no any free melittin existed in the particle suspensions of SSNS 
and DSNS (Figure 1.9).  
Investigate the pH responsiveness of nano-complexes by FRET  
To evaluate the stability of SSNS and DSNS, Förster resonance energy 
transfer (FRET) technology was employed.29 Before the fabrication of SSNS and 
DSNS, melittin and zwitterionic polymer were conjugated with Sulfo-Cy5-NHS 
and Cy3-NHS, respectively. Cy5-melittin was mixed with Cy3-SA-GCS and Cy3-
SA-GCS-SH to achieve SSNS and DSNS, respectively (Figure 1.10A). DSNS 
exhibited a higher FRET signal than SSNS (Figure 1.10B) at pH 7.4, indicating 
that DSNS was tighter than SSNS. To evaluate the nano-sting stability at 
different pH environments, FRET signal was recorded in the pH range from 7.4 to 
3.7. As the pH shifting from 7.4 to the IEPs of the polymers, the FRET intensities 
of both SSNS and DSNS increased and reached maximum at the pH close to the 
IEPs of the polymers, indicating the formation of more condensed nanoparticles. 
Similar to other zwitterionic macromolecules, SA-GCS showed lowest solubility at 
its IEP. The formation of water insoluble polymer would cause the condensation 
of SSNS and DSNS, and resulted in the highest FRET signal. SA-GCS displayed 
positive surface charge at pH lower than its IEP (Figure 1.4B), which would 
induce the repulsion between SA-GCS and positively charged melittin, similar to 
the scenario of nano-complex inside lysosome (Figure 1.1). As expected, both 
SSNS and DSNS displayed reduced FRET signal when environment pH was 
further decreased. At the pH of 3.7, SSNS showed a FRET intensity far less than 
that at pH 7.4, indicating the dissociation of nanoparticle. By contrast, the lowest 




7.4, suggesting that the formed disulfide bonds did restrict melittin from 
premature release upon the fluctuation of pH. There was one pH unit left shift of 
the FRET curve from their corresponding IEPs, which we think was due to the lag 
response of nano-complexes to the change in environmental pH. The dual 
secured effect was also evidenced by the slower melittin release from DSNS 
than SSNS, as well as more melittin released at pH 5.0 than pH 7.4 (Figure 
1.11). 
Investigate the hemolytic activity of nano-complexes 
To validate that the combination of zwitterionic polymer coating and 
disulfide crosslinking can effectively quench the hemolytic activity of melittin in 
DSNS, a hemolytic assay was carried out. SSNS and DSNS were incubated with 
red blood cells (RBCs) in PBS (pH 7.4) first, followed by centrifugation to 
separate the intact RBCs from the released hemoglobin. As shown in Figure 
1.12A, melittin lysed almost all RBCs at the concentration of 1 µM. The formation 
of SSNS partially inhibited the hemolytic activity of melittin. In contrast, there was 
no detectable red color in the supernatant of RBCs incubated with DSNS at the 
melittin concentration of 5 µM. The hemolytic activities of SSNS and DSNS were 
further quantified by UV spectrophotometer. Figure 1.12B showed that free 
melittin was highly lytic to RBCs, lysed almost 100% RBCs at 2 µM, which is the 
major obstacle for its clinical application. The hemolytic activity of melittin in 
SSNS was significantly quenched after its complexation with zwitterionic glycol 
chitosan. The residual hemolytic activity indicated that some melittin was 




disulfide bonds, DSNS did not show any hemolytic activity at 2 µM and only 
caused very few RBCs lyses at the concentration of 5 µM. Therefore, we proved 
that SSNS was safer than free melittin, while DSNS was almost non-toxic to 
RBCs up to the melittin concentration of 5 µM in pH 7.4 buffer.  
To investigate the intracellular membrane lytic activity of SSNS and 
DSNS, RBCs were co-incubated with melittin, SSNS, or DSNS in PBS (pH 5.0) 
buffer or PBS (pH 7.4) supplemented with 10 mM glutathione (GSH) to mimic the 
environments in the acidic lysosome and reducing cytosol, respectively. Acidic 
pH and reducing environment quenched the hemolytic activity of melittin (Figure 
1.13), which is consistent with others’ observation.30 SSNS at the concentration 
of 0.5 and 1.0 µM displayed much higher hemolytic activities in acidic pH than 
that in pH 7.4, suggesting the release of free melittin at low pH, which was 
consistent with our FRET observation in Figure 1.10B. In contrast, because of 
the restraint of disulfide bonds, acidic stimulus couldn’t trigger the release of 
melittin from DSNS (Figure 1.10B), and induced only slightly more RBCs lysis 
(Figure 1.13). As expected, the addition of 10 mM GSH to pH 7.4 buffer greatly 
enhanced DSNS’s hemolytic activity, reached the similar level as that of SSNS at 
the concentration of 2 and 5 µM (Figure 1.13). Furthermore, the hemolytic 
activity of DSNS was investigated in 50% serum containing buffer to mimicking 
blood. Figure 1.14 revealed that DSNS was also stable in blood simulating 
buffer, not causing RBC lysis. Based on these observations, we validated that 
DSNS should be safe during circulating in the blood stream while effectively 




Cellular uptake of nano-complexes  
To investigate how the stability of nano-complexes affects their cellular 
uptake, confocal microscopy was employed. SSNS and DSNS were fabricated 
as described above except that Cy3-SA-GSC was used instead of SA-GCS. 
More red spots were detected in cells treated with DSNS than SSNS (Figure 
1.15), which suggested that more DSNS nano-complexes entered cancer cells 
intact than their SSNS counterparts, while some SSNS had dissociated before 
endocytosis, evidenced by less Cy3 labeled SA-GCS uptake. Since DSNS was 
more stable than SSNS, as shown in Figure 1.10 and further prove by Figure 
1.12, DSNS won’t premature release melittin when contacting with serum protein 
and red blood cell (Figure 1.15). In contrast, SSNS was only stabilized by the 
electrostatic effect, which can be dissociated by the competing effect of serum 
protein. Therefore, more DSNS entered cancer intact than SSNS.  
Cell killing effect of nano-complexes 
Due to the limitation of SSNS associated unwanted hemolytic toxicity, 
further anticancer efficacy evaluation only included DSNS. NCI/ADR-RES 
(OVCAR-8 Adriamycin-resistant ovarian) cancer cells were co-cultured with free 
melittin and DSNS (melittin concentration of 5 µM) for 24 h.31 MTT reagent (3-(4, 
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was added after that. 
Living cells could convert MTT reagent into water insoluble purple crystals 
(Figure 1.16A). The absence of crystals in both melittin and DSNS treated cells 
indicated that the cells in both treatments were dead. To investigate the possible 
mechanism of cell death, we examined the cell morphology after treatment. Cells 




1.16B). In contrast to its free melittin treated counterpart, cells in Figure 1.16C 
kept their intact shape after DSNS treatment. Since melittin can attack cancer 
cells by forming pore structures on cell membrane 31c, we postulate that the cell 
death in melittin treatment group was mainly due to the loss of cell membrane 
integrity. DSNS, due to the dual-secured mechanism, could effectively enter 
cancer cells (Figure 1.15) and release melittin intracellularly (Figure 1.1 and 
Figure 1.13). Therefore, we postulate that DSNS treated cells were killed mainly 
due to the compromised membranes of internal organelles (e.g., mitochondria). 
After co-incubating with DSNS and followed by JC-1 staining, the emerging 
green fluorescence signals in DSNS treated cell (Figure 1.17) confirmed that 
cancer cells were killed due to mitochondria damage.  
The anticancer efficacy of DSNS was further quantitatively evaluated in 
four types of cancer cells, HCT-116 colon cancer cells, MCF-7 breast cancer 
cells, SKOV-3 ovarian cancer cells, and NCI/ADR-RES/OVCAR-8 ovarian 
(Adriamycin-resistant) cancer cells by MTT assay. As expected, both free melittin 
and DSNS showed dose-dependent cytotoxicity and could kill 100% of the 
cancer cells at a high dose (Figure 1.16). It is worthwhile to note that DSNS was 
more effective in killing HCT-116 cells. DSNS killed 100% of HCT-116 cells at the 
melittin concentration of 5 µM, at which free melittin could only kill 76% cancer 
cells (Figure 1.16D). Most importantly, DSNS only showed negligible hemolytic 
activity at the same concentration (Figure 1.12B). A similar anticancer effect was 
observed for MCF-7 breast cancer cells and SKOV-3 ovarian cancer cells 




Adriamycin-resistant ovarian cancer cells at the melittin concentration of 5 µM 
(Figure 1.16G), which have developed multidrug resistance. Altogether, we 
proved that anticancer capacity of melittin of DSNS, in contrast to other melittin 
carrier systems,21, 24a was fully retained. In addition, the polymer carrier itself was 
not toxic for all four tested cell lines (Figure 1.18). 
DISCUSSION 
In summary, we have fabricated DSNS nano-complexes through the 
electrostatic absorption of zwitterionic glycol chitosan and disulfide crosslinking to 
deliver melittin for cancer therapy. The hemolytic activity of melittin in DSNS 
could be completely quenched by our unique dual secured design. Due to the pH 
and redox potential dual responsiveness of DSNS, the wide-spectrum anticancer 
activity of melittin was fully retained, eradicating 100% of four types of tested 
cancer cell lines, including a drug resistant cell line. These studies demonstrated 
that the combination of zwitterionic polymer and redox sensitive bonds offer a 
new strategy for safe and effective therapeutic peptide delivery. The next step of 
research would be adding cancer cell targeting ligands, such as folic acid, 
anisamide, and disaccharide moiety of bleomycin,32 to the DSNS to further 
enhance its tumor specificity. 
MATERIALS AND METHODS 
Materials 
Glycol chitosan (GCS, Mw = 200 kDa; degree of deacetylation = 90%), 
potassium persulfate, sodium borohydride, succinic anhydride, melittin from bee 




pyridyldithio]-propionate (SPDP), tris(2-carboxyethyl)phosphine (TCEP), triethlyl 
amine (TEA), ethylenediaminetetraacetic acid (EDTA), and dimethyl sulfoxide 
(DMSO) were purchased from Sigma-Aldrich (St Louis, MO, USA). L-cysteine 
HCl and Ellman’s reagent were purchased from Thermo Scientific (Rockford, IL, 
USA). Dulbecco’s Modified Eagle Medium (DMEM) supplied with high glucose, 
trypsin and penicillin-streptomycin were purchased from Invitrogen (Carlsbad, 
CA, USA). Fetal bovine serum (FBS) was purchased from ATCC (Manassas, VA, 
USA).  
Depolymerization of glycol chitosan  
Glycol chitosan (Mw: 200 kDa) was first depolymerized to Mw 28 kDa 
using potassium persulfate, and then modified by reacting with succinic 
anhydride and SPDP sequentially. Briefly; glycol chitosan (400 mg) was 
dissolved in 37.5 ml of hydrochloric acid (2%, v/v). After that, potassium 
persulfate (67.5 mg) was added to the above glycol chitosan solution to start the 
depolymerization. The reaction was kept at 70 °C for 2 h and then stopped by 
adding sodium borohydride (300 mg). The reaction mixture was neutralized with 
sodium hydroxide (1 M). The resulting polymer was dialyzed (Spectra 7 MWCO: 
3500 Da) against ddH2O for 24 h followed lyophilization. Molecular weight of the 
polymer was obtained from GPC (Viscotek GPCmax VE 2001 GPC 
solvent/sample module, Viscotek VE 3580 RI detector and 270 Dual Detector) 
using 0.3 M acetic acid, 0.3 M sodium acetate, 0.02% sodium azide, 1% ethylene 





Acetylation of glycol chitosan with succinic anhydride (SA-GCS)  
Succinic anhydride (SA) was grafted onto the above yielded low molecular 
weight glycol chitosan (28 kDa) by acidification reaction. Briefly; glycol chitosan 
(30 mg) was dissolved in deionized water (6 mL) and succinic anhydride (4.17 
mg) was added under stirring. After 2 h of reaction at room temperature, the pH 
of the reaction mixture was adjusted to 8 with NaOH (1 M). The reaction was 
then allowed to proceed for another 2 h. The product was purified by dialysis 
(Spectra 7 MWCO: 3500 Da) against water (pH 9) for one day and lyophilized for 
48 h. The structural composition of modified glycol chitosan (SA-GCS) was 
characterized by 1H-NMR spectroscopy. The appearance of methylene proton 
peaks at δ = 2.4 to 2.6 ppm corresponding to succinic acid along with the glycol 
chitosan peaks at δ = 2.06, 2.75, 3.7 and 4.5 ppm (Figure 1.3). To determine the 
IEP of SA-GCS, ζ potential was measured as a function of pH using Zetasizer 
Nano-ZS (Malvern, UK). In a typical experiment, 0.5 mg/mL polymer solution was 
prepared in NaCl (10 mM), and the surface charges of SA-GCS at different pH 
were recorded.  
Modification of acetylated glycol chitosan (SA-GCS-SH)  
To generate thiol groups on SA-GCS, SA-GCS was reacted with SPDP. 
The introduced disulfide bonds were then cleaved by TCEP to yield free thiol 
groups. Briefly; SA-GCS (60 mg) was first dissolved in dimethyl sulfoxide (10 
mL). TEA (300 µL) and SPDP (21.63 mg) were then added under stirring. After 
overnight reaction at room temperature, the disulfide bonds were cleaved by 




by dialysis (Spectra 7 MWCO: 3,500 Da) against 10 mM EDTA (24 h) followed by 
ddH2O (24 h). The product was obtained after lyophilization for 48 h and stored 
at -20 °C. IEP of SA-GCS-SH was determined in a similar way as SA-GCS. The 
concentration of thiol group was quantified by DTNB assay. The number of thiol 
groups per polymer molecule was found to be 8.7 as calculated by DTNB assay.  
Nano-complexes preparation and characterization 
Melittin and SA-GCS-SH were dissolved in Tris buffer saline (TBS) pH 7.4 
to get 0.1 mg/mL and 5 mg/mL, respectively. Then, 1 ml melittin solution was 
incubated with different amounts (0.1 to 4 mL) of SA-GCS-SH solution for 1 h at 
room temperature to get non-crosslinked complexes (single secured nano-sting, 
SSNS). To develop cross-linked complexes (dual secured nano-sting, DSNS), 
SSNS was aerially oxidized for 2 h at room temperature. SSNS and DSNS were 
freeze-dried with 5% trehalose and stored at -20 °C until use. The binding 
efficiency of SA-GCS-SH was measured by measuring the fluorescence of free 
melittin. Free melittin from the complexes was separated by centrifugal filtration 
at 14,000 rcf for 8 min using Nanosep 30 K Omega (Pall corporation, USA) and 
the concentration was determined by measuring its fluorescence (λexi=280nm, 
λemi=350 nm) using a SpectraMax M5 Multi-Mode Microplate Reader (Molecular 
Devices). Nano-complexes prepared at the ratio of 200:1 (polymer: melittin, w/w) 
were used for the following experiments.  
The size and surface charge (ξ-potential) of the complexes were 
measured using a Zetasizer Nano-ZS (Malvern, UK) at pH 7.4. The morphology 




800 TEM) using a formvar/carbon coated Copper Grids (Electron Microscopy 
Science). The original complexes solution (5 µL) was dropped on a grid, washed 
with ddH2O (3 ×) to remove the remaining salt, and dried with a tissue paper. 
HPLC determination of melittin was carried out with a Waters 2996 instrument 
equipped with a photodiode array detector and a hypersil gold column (250 × 4.6 
mm, Fisher); mobile phase: mixture of acetonitrile and water supplemented with 
0.1 % TFA (linear gradient from 4:96 to 64:36, v/v, over 60 min); flow rate: 1.5 
mL/min; detection: 220 nm. The retention time for melittin was 41.6 min. 
Standard solutions were prepared by dissolving melittin in ddH2O followed by a 
series of dilutions. Melittin stock solution was prepared at 100 μg/mL. For sample 
preparation, 50 μg of SSNS and DSNS were dissolved in 500 μL ddH2O and the 
free melittin solution was collected by centrifugation at 13,000 rcf for 30 min twice 
with Nanosep centrifugal device 10K Omega (Paul life sciences). The resulting 
filtrate (50 μL) was injected for HPLC determination. No peak detected at 41.6 
min suggested that both SSNS and DSNS were free of free melittin (Figure 1.9). 
FRET measurement 
The donor fluorescence dye Cy3-NHS was chemically conjugated with 
SA-GCS and SA-GCS-SH prior to forming the complex. Similarly, the receptor 
fluorescence dye Sulfo-Cy5-NHS was conjugated with melittin. The conjugated 
Cy3 amounts in SA-GCS and SA-GCS-SH were adjusted carefully to ensure that 
the same conjugation efficiency was achieved, which was further validated by 
measuring the fluorescence intensity of Cy3 with a SpectraMax M5 Multi-Mode 




and Cy5-labeled melittin, while DSNS was fabricated from Cy3-labeled SA-GCS-
SH and Cy5-labeled melittin. Cy3 and Cy5 dual-labeled SSNS and DSNS were 
prepared following the same protocol except that the DSNS needed aerial 
oxidation. Therefore, the amount of each dye in SSNS and DSNS was the same. 
The titration of nano-complex was carried out by adding 0.1 M HCl and NaOH to 
adjust pH to the pre-designed values. Both SSNS and DSNS samples were 
loaded into Coring® 96 well black flat bottom plates. Samples were excited at 
500 nm with the cutting off 530 nm. The entire fluorescence spectra (from 530 
nm to 750 nm) of both nano-complexes were then recorded as a function of the 
pH with the help of a SpectraMax M5 Multi-Mode Microplate Reader (Molecular 
Devices).  
Release kinetics of SSNS and DSNS 
Cy5 labeled melittin were fabricated into SSNS and DSNS as described 
above. SSNS and DSNS samples (2 mL) were loaded into dialysis bags (MWCO: 
6000-8000). The dialysis bags were put into different media (pH 7.4,10 mM PBS 
and pH 5, 10 mM acetic acid buffer) at 37 °C under continually stirring. At 
predesigned time (1, 2, 4, 8 h), 1 mL sample was taken and supplemented with 1 
mL corresponding fresh medium. Samples were lyophilized and re-suspend in 
200 μL ddH2O. To calculate the release amount of melittin, the originally labeled 
Cy5-melittn was employed to obtain standard curve with the help of a 
fluorescence microplate reader. The fluorescence intensities of released samples 






Sprague Dawley Rat whole blood was purchased from Bioreclamation 
LLC (NC, USA). Briefly, RBCs were washed with NaCl (210 mM) until no red 
color was visible in the supernatant. The washed RBCs were used to compare 
hemolytic effects of melittin, SSNS and DSNS using DI water as positive control 
and PBS (pH 7.4) as negative control. Melittin of different concentrations (0.1 to 5 
µM) and SSNS or DSNS (equivalent with free melittin) were added to fixed 
number of washed RBCs (2.5×107 cells) and incubated at 37 ºC for 1 hour. The 
release of hemoglobin was quantified by measuring the absorbance at 405 nm of 
the supernatant in a microplate reader (ELX808, Bio-Tech Instrument) after 
centrifugation at 300 rcf for 2 minutes. The results were expressed relative to the 
reference standard. To investigate the effect of pH and redox potential on the 
hemolytic activity of SSNS and DSNS, nano-complexes were co-incubated with 
RBCs in PBS (pH 5.0) and PBS (pH 7.4) supplemented with 10 mM GSH, 
respectively. The stability of DNSN was also tested by co-incubating RBCs with 
DSNS in PBS buffer containing 50% serum.  
Confocal microscopy 
HCT-116 cells were seeded at a density of 2×104 cells per chamber slides 
and allowed to grow for 24 h. SA-GCS and SA-GCS-SH were conjugated with 
Cy3 followed by excessive dialysis to remove free Cy3. The purified Cy3 labeled 
polymer were used to prepare SSNS and DSNS. After treated with SSNS and 
DSNS for 2 h at 37 °C in a 5% CO2 incubator, cells were washed with PBS three 




Hoechst33342 1 μg/mL (Invitrogen) and washed again with PBS for 3 times. 
Finally, cells were imaged with confocal laser scanning microscopy (Zeiss LSM 
700).  
JC-1 Staining 
HCT 116 cells were seeded in each petri dish at density of 300K cells per 
dish. After overnight incubation, cells were treated with 2 μM Melittin or DSNS for 
1 h. Cells were then stained with JC-1 for 30 min (Cayman chemical, MI), and 
observed under confocal microscope using FITC and Texas Red channels.  
Cytotoxicity assay 
The anticancer activities of melittin and DSNS in MCF-7, HCT-116, SKOV-
3 and NCI/ADR-res cells were evaluated by MTT assay using melittin as a 
positive control and non-treated cells as a negative control. The cells were 
seeded in 96-well plates at an initial density of 12,000 cells/well in 150 μL of 
DMEM medium supplemented with 100 U penicillin/streptomycin and 10% FBS. 
After 24 h, the medium was replaced with 150 µL of fresh medium containing 
DSNS and melittin (corresponding to 0.1 to 10 µM melittin) and incubated for 
another 24 h. After the defined time of co-incubation, the media were replaced 
with 100 µL fresh media containing 1 mg/mL MTT reagent and incubated for 4 h. 
The formed MTT crystal was dissolved with a stop solution and the finally optical 
density of the medium was measured using a microplate reader (ELX808, Bio-
Tech Instrument, Inc) at λ = 595 nm. The cytotoxicity of melittin and DSNS was 
calculated as relative to the control group (untreated cell). The cytotoxicity of 







Figure 1.1 Schematic illustration of complex formation and reaction scheme of 
the polymer synthesis. (A) Schematic illustration of the formation and intracellular 






















Figure 1.3 The 1H-NMR spectra in D2O of GCS, SA-GCS, SA-GCS-PDP, and 







Figure 1.4 IEP measurement of polymers. (A) The structure of SA-GCS-SH. (B) 






Figure 1.5 Binding efficiency characterization of nano-complexes. (A) Binding 
efficiency of nano-complex formed at different polymer/melittin (w/w) ratios. (B) 
Binding efficiency of SSNS and DSNS at different polymer/melittin (w/w) ratios. 















Figure 1.7 Transmission electron microscopy images. (A) SSNS and (B) DSNS. 






Figure 1.8 The surface charge of complex was determined by phase analysis 







Figure 1.9 HPLC spectra of SSNS and DSNS for the detection of free melittin in 








Figure 1.10 The FRET produced by DSNS. (A) The schematic of FRET 
produced by DSNS and SSNS. (B) The measured FRET intensities of DSNS and 













Figure 1.12 Hemolytic assay after incubation of melittin, SSNS, and DSNS with 
RBCs. (A) Images of RBCs after hemolytic assay. (B) The hemolytic activity of 






Figure 1.13 Hemolytic activity of melittin, SSNS, and DSNS at different pH 















Figure 1.15 Uptake of SSNS and DSNS by confocal microscopy. Confocal 
microscope images of HCT-116 colon cancer cells after incubation with SSNS 
and DSNS for 2 h. Scale bars are 10 μm in all images (Blue-Hoechst, Red-Cy3 






Figure 1.16 Cytotoxicity evaluation of DSNS. The light microscopy images of the 
morphologies of NCI/ADR-RES cells treated with 5 µM melittin. (A) Control, (B) 
free melittin, (C) DSNS. (D-G) Cytotoxicity of DSNS and melittin treatments in 









Figure 1.17 Mitochondrial membrane potential changed with the incubation with 
melittin and DSNS. Confocal microscope images of HCT-116 colon cancer cells 
after incubation with melittin and DSNS for 1 h and stained with JC-1. Scale bars 
are 10 μm in all images. Green fluorescence indicates depolarized membrane 
potentials (JC-1 monomer form) due to the damaged mitochondria function, and 







Figure 1.18 Cytotoxicity of SA-GCS-SH. Polymers at the corresponding melittin 
concentration of 0.1 to 10 μM were tested in SKOV-3, MCF-7, NCI/ADR-RES, 
and HCT-116 cancer cells. 
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Gold nanosphere gated mesoporous silica nanoparticle responsive to 
NIR light and redox potential as a theranostic platform for cancer 
therapy 2 
ABSTRACT  
A gold/mesoporous silica hybrid nanoparticle (GoMe), which possesses 
the best of both conventional gold nanoparticles and mesoporous silica 
nanoparticles, such as excellent photothermal converting ability as well as high 
drug loading capacity and triggerable drug release, has been developed. In 
contrast to gold nanorod and other heat generating gold nanoparticles, GoMe is 
photothermal stable and can be repetitively activated through NIR irradiation. 
Doxorubicin loaded GoMe (DOX@GoMe) is sensitive to both NIR irradiation and 
intracellularly elevated redox potential. DOX@GoMe coupled with NIR irradiation 
exhibits a synergistic effect of photothermal therapy and chemotherapy in killing 
cancer cells. Furthermore, 64Cu-labeled GoMe can successfully detect the 
existence of clinically relevant spontaneous lung tumors in a urethane-induced 
lung cancer mouse model through PET imaging. Altogether, GoMe can be 





Gold nanoparticles, including gold nanosphere (GNS), gold nanorod 
(GNR), gold nanoshell (GNSH), and gold nanocage (GNC), have attracted 
tremendous attentions during the past decade and have been extensively 
explored in biomedical applications, such as drug and gene delivery, disease 
detection, treatment, and response monitoring, due to their excellent 
biocompatibility, and easy surface modification.33 Upon irradiation, gold 
nanoparticles generate heat attributable to the localized surface plasmon 
resonance (LSPR) phenomenon.34 By manipulating their shape, size, and 
geometry, the LSPR peak of GNR, GNSH, and GNC can be tuned to near-
infrared (NIR) region, also called tissue transparent window (650-900 nm), within 
which light can penetrate deeply.35 Because of that, upon NIR irradiation, these 
gold nanoparticles generate heat and can be applied for photothermal 
therapy.34a, 36 Although gold nanoparticles have been evaluated in numerous 
systems and proven to be promising in photothermal therapy and drug delivery, 
there are several intrinsic properties limiting their translation from bench to 
clinical practice. First, due to their poor photothermal stability, traditional gold 
nanoparticles gradually lose their photothermal converting capacity upon 
repetitive NIR irradiation. It has been well documented that the shape and 
extinction of GNR changed after NIR laser irradiation and resulted in lower heat 
generating capacity after each heating/cooling cycle.37 Similar scenarios also 
have been observed in GNSH and GNC if the generated heat could not be 




gold nanoparticles are not good drug carriers either due to limited drug loading 
capacity or poorly controlled drug release profile.39 Furthermore, although 
tremendous efforts have been devoted, how to effectively integrate both 
photothermal therapy and chemotherapy modules into one system remains a 
challenge, especially when repetitive activation is needed. 
Similar as gold nanoparticles, last decade also witnessed increasing 
attention gained by mesoporous silica nanoparticle (MSN) due to its high and 
versatile drug loading capacity as well as good biocompatibility. Numerous MSN 
based carrier systems have been developed for the delivery of drugs, peptides, 
DNAs, and siRNAs. To better control the release kinetics of their payloads, many 
gatekeepers have been explored, such as polyelectrolytes,40 macrocyclic organic 
molecules,41 and inorganic nanoparticles.42 Generally, these MSN delivery 
systems are responsive only to the changes in the physiological environment, 
such as pH and redox potential. Once the MSN is administrated in vivo, the drug 
release profile will be out of the control of the clinician and be totally relying on its 
fabrication method and biodistribution. To overcome the limitations of existing 
gold nanoparticles and MSNs in photothermal therapy and drug delivery, we 
developed a gold/mesoporous silica hybrid nanoparticle (GoMe) by conjugating 
gold nanospheres (GNS) onto the surface of MSN (Figure 2.1A) to take 








Gold/mesoporous silica hybrid nanoparticle (GoMe) fabrication 
Thiolated MSN was fabricated by the co-condensation of (3-mercaptopropyl) 
trimethoxysilane (MPTMS) with tetraethyl orthosilicate (TEOS). With CTAB and 
F127 applied as structure directing agents, these silica sources were able to be 
constantly hydrolyzed. After the nanoparticle grew to a certain size, the template 
of CTAB was removed by ion exchange with ammonia nitrate. TEM revealed that 
most MSNs are in spherical or oval shape with a size of 50.87 ± 10.69 nm 
(Figure 2.1B). The N2 sorption measurement revealed that the pore size of MSN 
is about 2-3 nm (Figure 2.2), with a surface area of 858 m2/g. The accessible 
thiol groups on the MSN were quantified with Ellman’s reagent using cysteine as 
a reference standard. The amount of thiol groups in MSNs was 31 μmol/g. The 
super stable gold nanosphere (GNS) was synthesized according to literature with 
minor modification.43 Thiolated polyethylene glycol (PEG-SH, Mw=2000 Da) was 
added into the gold isopropanol alcohol solution before the formation of GNS. 
The resulting PEG-GNS was spherical with a diameter of 3.93 ± 0.70 nm (Figure 
2.1C). The resulting PEG-GNS was further functionalized through a two-step 
procedure by conjugating PEG-GNS with cysteamine first, followed by reacting 
with homemade 2-(pyridin-2-yldisulfanyl)ethyl acrylate (PDA) via Michael addition 
reaction to yield PDA-GNS as shown in Figure 2.1A. DTNB assay revealed that 
about 200 PDA molecules were anchored to each GNS. PDA-GNS was grafted 
onto MSN through thiol-disulfide exchange reaction (Figure 2.1A) by simply 




investigate the assembly between GNSs and MSNs. Figure 2.1C showed that 
most GNSs were evenly attached to the surface of MSNs. This gold 
nanosphere/mesoporous silica nanoparticle hybrid assembly was named as 
GoMe. To our surprise, only a few free GNSs were detected after the reaction, 
indicating the high efficiency of the conjugation reaction. The success of grafting 
of GNS onto MSN was further confirmed by SEM image and SEM/EDX analysis. 
The evenly distributed small spherical dots on the bigger balls (Figure 2.3) and 
the presence of gold element (Figure 2.4 and 2.5) indicated that GoMe had a 
structure as shown in Figure 2.1A. Zetasizer found that GoMe carried slightly 
negative surface charge (-5.92 ± 0.75 mV, Figure 2.6). Due to the existence of 
PEG outer layer, GoMe was stable in culture medium containing 10% FBS 
(Figure 2.7), and no obvious size change and aggregation were observed after 
two months of incubation. The size of GoMe determined by dynamic light 
scattering (DLS, 141.7 nm) was larger than that observed by TEM (54.71 ± 9.63 
nm), which is because that TEM measures physical size of the dried particles 
while DLS measures their hydrodynamic diameter (including the water layer 
surrounding the particle). 
Photothermal property characterization  
To monitor the fabrication progress of GoMe, UV-Vis spectrophotometer 
was employed by recording the absorbance from 400 to 1000 nm during the 
reaction. Figure 2.8A showed that the absorbance peak of the reaction mixture 
at 524 nm decreased over time and slightly shifted to long wavelength direction, 




photothermal properties of the reaction mixture changing with the progress of the 
reaction, the reaction suspension was irradiated with NIR laser (808 nm, 2.83 
W/cm2) for 10 min at predesigned time intervals and its temperature was 
monitored with a FLIR i7 thermal imaging camera and recorded every 30 sec. 
Before the mixing, the aqueous nano-suspension of MSN produced none while 
GNS produced little heat under the NIR irradiation (Figure 2.8B). To our 
surprise, after 12 h of reaction, the temperature of the mixture of MSN and GNS 
raised 21.2 °C after irradiation (Figure 2.8B). Furthermore, the longer the 
reaction time, the higher the temperature reached.  The mixture after 24 h of 
reaction could be heated to 52.8 °C (30 °C increase) upon the same intensity and 
length of NIR irradiation. The photothermal conversion efficiency of GoMe was 
29.65%, which is slightly higher than the reported GNSH (25%) while lower than 
GNR (50%).44 
To probe the mechanism for the mixture of GNS and MSN generating heat 
upon NIR laser irradiation, TEM was employed to observe the morphology 
change during the reaction. The reaction mixture was centrifuged to remove 
unconjugated GNS before loaded onto copper grids for TEM observation. Figure 
2.8C showed that GNSs can be conjugated onto MSN within 2 h. Longer reaction 
time resulted in a higher GNS decorating density on the surface of MSN (Figure 
2.8D and 2.8E). Altogether, higher decorating density of GNS on GoMe led to a 
higher absorbance in the NIR region, which opened the window for the 
biomedical application of GoMe using a NIR laser (Figure 2.8A). As a 




upon the NIR laser irradiation (Figure 2.8B). Figure 2.9 revealed that GoMe 
exhibited a concentration-dependent photothermal heating effect. Therefore, a 
desired photothermal heating curve can be achieved by simply tuning the 
concentration of GoMe. Photothermal stability is a vital property for the success 
of photothermal therapy, especially when repetitive treatment is necessary for the 
management of recurrent cancer. To evaluate the photothermal stability of 
GoMe, aqueous suspension of GoMe was repetitively irradiated with the 808 nm 
NIR laser (10 min on and 20 min off) at the light intensity of 2.83 W/cm2. The 
temperature of the nano-suspension was monitored as described above. GNR 
(aspect ratio of 3.89 and peak absorbance of 804 nm) synthesized according to 
literature was employed as a control.45 GNR at a concentration that could 
produce heat to reach similar temperature as that of GoMe was irradiated in 
parallel. Figure 2.10 showed that the temperature of both GoMe and GNR 
suspensions increased rapidly upon laser irradiation and reached 74 °C in 10 
min. As expected, the repetitive heating of GNR suspension resulted in 
decreased peak temperatures, declined from 74 to 65.8 °C during the second 
heating cycle and further dropped to 48.5 °C after 6 cycles of laser irradiation 
induced heating/cooling. In an apparent advancement to the field, GoMe 
suspension could reach the same peak temperature after 6 heating/cooling 
cycles, and achieved even higher peak temperature after 24 h of resting period, 
which suggests that GoMe was stable in keeping its photothermal property 
during laser irradiation induced heating/cooling process. Such stability is critical 




GNSs were grafted onto MSN through disulfide bonds, the photothermal property 
of GoMe in reducing environment was further investigated. Figure 2.11 showed 
that GoMe only slightly decreased its peak temperature in an environment 
containing 10 mM GSH, suggesting that most of GNSs were still attached to 
MSN. As we have confirmed that each GNS had 200 thiol reactive PDA groups, it 
is reasonable to postulate that every GNS was connected with MSN through 
multiple disulfide bonds. Therefore, at any given time, GSH only cleaved partial 
of those disulfide bonds for each GNS and loosened the binding between GNS 
and MSN. More importantly, repetitive heating/cooling in reducing environment 
did not change its photothermal converting capacity (Figure 2.11). Therefore, 
GoMe would retain its competence in generating heat upon NIR irradiation in an 
intracellular environment, where it has high GSH level.46 
To probe why GoMe was stable during the NIR laser irradiation induced 
heating/cooling cycles, while GNR was instable, the UV-Vis spectra of GoMe and 
GNR after each cycle were recorded. The UV-Vis absorbance of GoMe only 
marginally changed after 6 cycles of heating/cooling (Figure 2.12A), while the 
absorbance of GNR significantly diminished in the NIR region (Figure 2.12B). To 
investigate the morphologies of the GNR and GoMe after above treatment, TEM 
was employed. Figure 2.12D proved that the morphology of GoMe remained 
intact after laser irradiation. By contrast, some GNRs changed their shape 
significantly after 5 cycles of laser irradiation, becoming shorter and fatter or 
round (Figure 2.12F). This rod-to-sphere shape transformation was due to the 




nanoparticles melt at high temperature and form gold nano-droplet (or so called 
nanosphere), similar shape transformations also have be documented for gold 
nanoshells and gold nanocages.38c As a consequence of losing their original 
geometries, these gold nanoparticles showed a compromised photothermal 
property. However, GoMe, which was fabricated from GNS and MSN, kept its 
shape unchanged, since GNS remained its original spherical after melting. 
Therefore, GoMe kept its photothermal capacity intact over multiple 
heating/cooling cycles. 
Drug release kinetics measurement 
To investigate whether the decoration of GNS on the surface of MSN 
could affect the release profile of its payload, anticancer drug doxorubicin (DOX) 
was adopted as a model drug and loaded into MSN as described by literature.33 
Due to its high surface area and pore volume, GoMe achieved 28% drug loaded 
content. Because DOX is a potent anticancer drug, DOX loaded GoMe 
(DOX@GoMe) of 4.58% drug loading content was adopted for the in vitro assay. 
However, in drug release kinetics study, the DOX@GoMe of 28% drug loading 
content was employed to achieve a more accurate drug release profile.  
An ideal drug carrier should be premature-release free before reaching its 
target. Furthermore, for a desired delivery system, the release of its payload 
should be either spontaneously responsive to the stimuli from its target or 
remotely controlled by external signals. To investigate the release kinetics of 
DOX from GoMe, DOX@GoMe was suspended in phosphate buffer (PBS, pH 




circulating blood and cytosol, respectively. Researchers found that surface non-
modified MSN can easily aggregate in aqueous medium,48 which could result in 
false release profile. For fair comparison, DOX loaded MSN (DOX@MSN) was 
also stabilized though PEG-SH surface modification. Figure 2.5A showed that 
DOX@MSN released more than 28.8% of its payload within 10 h of incubation in 
PBS, suggesting that unsealed MSN was not a desired carrier. Interestingly, 
GoMe, MSN decorated with GNS, released much less of DOX (8.3%) within the 
same period of time, indicating that GNS could serve as a plug to prevent DOX 
from leaking out from the pores of MSN during circulating in blood stream. Since 
GNS was conjugated onto the surface of MSN through disulfide bonds, we 
further investigated the responsiveness of GoMe to reducing environment by 
dispersing it in PBS supplemented with 10 mM GSH. As expected, GoMe 
released much more DOX in reducing environment (66.4% of DOX within 24 h) 
than that in PBS (10.3%), demonstrating that GoMe was a good carrier for 
intracellular drug delivery. As we already proved that GoMe could efficiently 
convert NIR laser irradiation into heat, we further investigated the effect of NIR 
irradiation on drug release by applying irradiation (10 min laser on in every 24 h 
period) on the GoMe nano-suspension. Remarkably, Figure 2.13B showed that 
10 min of NIR irradiation induced more than 23% immediate DOX release. The 
removal of laser irradiation promptly slowed down the drug release. Moreover, 
the re-introducing of laser irradiation could accelerate drug release repetitively. 
The first time NIR irradiation triggered more drug release than the later ones, 




first irradiation while later stimuli induced the release of encapsulated drugs from 
the pores of MSN. This light activable two-stage drug release pattern can be 
utilized to meet the clinical setting in drug administration by providing both 
loading dose and maintenance dose. 
Observation of GoMe by confocal fluorescent and dark-field microscopies 
To explore the potential of using GoMe as a carrier to deliver drug into 
cancer cells, DOX-loaded GoMe was co-incubated with A2058 melanoma cells 
for 3 h, and then observed with a confocal microscope. The red fluorescence 
signals in Figure 2.14F proved that GoMe loaded DOX could effectively enter 
A2058 cells. To further confirm that GoMe entered cancer cells, the above cells 
were also observed with a dark-field microscope. Scatter light signals (yellow and 
red dots) collected inside A2058 cells (Figure 2.14J) through a dark-field 
detector proved that GoMe could be taken up by cancer cells. 
Cell killing effect of GoMe  
Figure 2.15 displayed that GoMe raised medium temperature from 21.8 to 
34.6 and 50.3 °C within 10 min of laser irradiation at GoMe concentrations 
corresponding to 1.67 and 5 μM DOX, respectively. Since GoMe could generate 
heat and raise medium temperature upon NIR laser irradiation, we first 
investigated its photothermal therapy effect on the cancer cells through 
Live/Dead cell assay. A 2058 cells were co-incubated with blank GoMe at the 
corresponding Dox concentration of 5 μM and coupled with NIR laser irradiated 
for 10 min before the Live/Dead cell assay, and then visualized with a fluorescent 




(Figure 2.16A). It was also noted that blank GoMe treated cells (Figure 2.16B) 
did not show any morphology difference as compared with the non-treated ones, 
suggesting GoMe itself was not toxic. By contrast, cells treated with blank GoMe 
and laser irradiation dramatically changed their morphology, showing round 
shape (Figure 2.16C). It was also noticed that the cell density in Figure 2.6C was 
much lower than the group without receiving laser irradiation, which was due to 
the detaching of cells as a result of apoptosis and subsequently being removed 
during the washing procedure. In addition, a significant portion of cells in Figure 
2.16C were stained in red, confirming that GoMe coupled with NIR irradiation 
could effectively kill cancer cells. 
We have confirmed that NIR laser irradiation could trigger the release of 
DOX from GoMe, and also proved that photothermal effect of blank GoMe could 
kill cancer cells. To investigate the cell killing efficacy of DOX@GoMe coupled 
with NIR irradiation, A 2058 cells receiving different treatments were analyzed by 
MTT assay. Due to the potential residual of cetyl trimethylammonium bromide 
(CTAB) in the MSN, blank GoMe showed some cytotoxicity. As expected, the 
application of NIR irradiation enhanced the cell killing effect of GoMe (Figure 
2.16D), especially for GoMe at the concentration of 5 μM. Because the capping 
effect of GNS and consequent slower drug release, DOX@GoMe was less 
potent than DOX@MSN in killing cancer cells. Furthermore, Figure 2.16D also 
evidenced that the DOX@GoMe coupled with NIR irradiation did show superior 
anticancer efficacy than either GoMe coupled with NIR irradiation or 




DOX@GoMe could kill cancer cells by the combination effect of photothermal 
ablation and boosted drug release and subsequent enhanced chemotherapy. It is 
worth noting that the effect of NIR irradiation only became significant when GoMe 
concentration reached 2 μM, at which GoMe could generate enough heat to 
ablate cancer cells and augment drug release. The combination index (CI) 
analysis further revealed that the combination of DOX@GoMe and NIR 
irradiation exhibited synergistic effect at the DOX concentration 5 μM (CI value = 
0.50).49 Therefore, to warrant the synergistic effect between DOX@GoMe and 
NIR irradiation, high retention of DOX@GoMe in the targeted tissue or cells is 
required. 
In vivo tumor detection  
To endow the PET imaging function to GoMe, DOTA was conjugated onto 
GoMe nanoparticles by adding maleimido-mono-amide-DOTA. With the help of 
conjugated DOTA, the yield for GoMe 64Cu-labeling was above 98%, which 
suggests that GoMe is a good carrier for radiopharmaceuticals. To validate that 
64Cu-labeled GoMe can be used as a tool for cancer detection, a clinically 
relevant spontaneous lung tumor model was employed. The 3 small tumors in 
the lung (previously revealed by a ClinScan MRI system as shown in Figure 
2.17A) were clearly detected by PET at both 6 h (Figure 2.17B and C) and 20 h 
(Figure 2.17D) post-administration, suggesting the high retention of GoMe in the 
tumor, which proved that GoMe is good tool for the cancer detection. Similar as 
other nanoparticles, significant amount of GoMe nanoparticles accumulated in 




abdomen (colon and rectum) from 6 h to 20 h revealed the rout for GoMe to be 
cleared from the body.  
DISCUSSION 
Various gold/silica hybrid nanoparticles have been explored as tools for 
bioimaging and drug carrier. Lee et al. revealed that α-synuclein-coated gold 
nanoparticle decorated MSN could release its payloads upon the intracellular 
Ca2+ stimulus.50 Aznar et al. developed a gold/MSN hybrid system through the 
formation of boronate esters. Due to the hydrolysis of boroester bonds at acidic 
pH and light induced heat, low pH and light can be used to trigger the release of 
its cargo.42a In addition, Sharma et al. also found that gold nanoparticle coated 
silica nanoparticles could produce strong signals for magnetic resonance imaging 
(MRI) and photoacoustic tomography (PAT).51 In our design, gold nanospheres 
were grafted onto the surface of MSN through disulfide bonds, which endowed 
the intracellular redox potential responsiveness to GoMe. The surface-assembled 
GNS can be considered as a structure well-defined assembly of “chainlike gold 
nanoparticles”,52 or a discontinuous form of gold nanoshell, both of them can 
efficiently generate heat upon NIR irradiation. In contrast to its continuous 
counterpart, GoMe kept its original shape after NIR irradiation due to the distance 
between each GNS and the support of MSN. Consequently, GoMe exhibited 
stable photothermal property. Because the release kinetics of GoMe is super 
sensitive to the NIR irradiation, DOX@GoMe showed synergistic effect in killing 
cancer cell upon NIR irradiation. Since the first in vitro report of mesoporous 




explored its application for tumor growth inhibition in vivo.54 However, none of 
them have been utilized for cancer detection. Due to the abundance of PDA 
segments on the GNS, GoMe could be conveniently modified with DOTA and 
achieved excellent chelating capacity needed for PET imaging. To the best of our 
knowledge, GoMe is the first gold/mesoporous silica hybrid nano-system which is 
capable of both detecting clinically relevant spontaneous tumor and achieving the 
synergetic effect of photothermal therapy and chemotherapy in killing cancer 
cells. To further enhance the sensitivity of its cancer detection capacity and boost 
its anticancer efficacy, the next step research will incorporate tumor targeting 
ligands, such as RGD peptide, folic acid, and anisamide, which target cancer 
cells overexpressed integrin,55 folate,55b, 56 and sigma-2 receptors,32b, 57 
respectively, into GoMe. In summary, a photothermal stable gold/mesoporous 
silica hybrid nanoparticle (GoMe), which possesses the merits of both 
conventional gold nanoparticles and mesoporous silica nanoparticles, such as 
good photothermal converting ability and high drug loading capacity, has been 
developed. In contrast to other MSN based system, GoMe is well dispersed in 
serum containing medium. Contrary to GNR and other heat generating gold 
nanoparticles, GoMe is stable in structure and maintains its photothermal 
converting capacity after repetitive NIR irradiation. The release of drug from 
GoMe can be triggered by both intracellularly elevated redox potential and NIR 
irradiation. The localization of doxorubicin loaded GoMe can be detected by both 
fluorescence and dark-field microscopies. In addition, the combination of 




concentration 5 μM through the integration of photothermal therapy and 
chemotherapy. Furthermore, PET imaging proved that GoMe is a good tool for 
the detection of clinically relevant spontaneous lung tumor. Based on these 
promising in vitro and in vivo results, further studies will focus on the 
pharmacokinetics of GoMe and utilizing it as an effective tool for image-guided 
cancer therapy. 
MATERIALS AND METHODS 
Materials 
Terraethylorthosilicate (TEOS), (3-mercaptopropyl)trimethoxysilan)  
(MPTMS), hexadecyltrimethyl ammonium bromide (CTAB), sodium hydroxide 
(NaOH), pluronic® F-127, ammonium nitrate, methanol, gold chloride trihydrate, 
cysteamine hydrochloride, 2,2’-dipyridyl disulfide, triethylamine (TEA), 
doxorubicin (DOX), and sodium borohydride (NaBH4) were purchased from 
Sigma-Aldrich. PEG2000-SH was purchased from Laysan Bio. Ethanol and 
acetic acid were acquired from Fisher Scientific. 
Synthesis of mesoporous silica nanoparticles (MSN) 
The MSN was synthesized in a dual surfactant system using a classic fast 
self-assembling method containing both the cationic surfactant cetyl 
trimethylammonium bromide (CTAB) and non-ionic surfactant triblock polymer F 
127 to obtain a good suspending nano-sized MSN. In a typical synthesis, CTAB 
(50 mg) and F 127 (40 mg) were dissolved in 24 mL DI water. After that, NaOH 
aqueous solution (175 μL, 2M) was added into the above mixture. The reactants 




dropwise to the above solution followed by 3-mercaptopropyl trimethoxysilan 
(MPTMS, 20 μL). A white precipitant was formed after a few minutes and the 
mixtures were allowed to stir for 2 h at 80 °C. The crude product was collected by 
centrifugation at 16,000 rcf for 15 min. CTAB was removed through ion exchange 
by washing in ethanol solution of NH4NO3 at 50 °C. This process was repeated 
for 3 times, followed by extensively washing with ethanol and the purified product 
was stored at 4 °C in ethanol solution. 
Synthesis of PEG stabilized gold nanosphere (PEG-GNS) 
The super-stable gold nanosphere was synthesized according to literature 
with minor modification.43 Briefly, gold (III) chloride trihydrate (12 mg) was first 
dissolved in 18 mL isopropyl alcohol and followed with the addition of 0.2 mL 
acetic acid. Thiolated polyethylene glycol (PEG-SH, MW=2000 Da) (15.24 mg in 
2 mL isopropyl alcohol) was added into the gold alcohol solution. The mixture 
was stirred for 1 h at room temperature following the addition of sodium 
borohydride (37.84 mg in 1.5 mL methanol). The reaction mixture was stirred 
vigorously overnight at room temperature. After overnight reaction, the mixture 
was centrifuged for 30 min (2500 rcf) to remove large particles. The resulting 
supernatant was precipitated in hexane. The precipitant was re-dispersed in 5 
mL DI water. To remove free PEG-SH from gold nanoparticle, the PEG-GNS was 
purified by repeatedly washing with water in a Millipore Centricon (MW 
CO=10,000 Da). The successful anchoring of PEG-SH onto gold nanosphere 
was confirmed by 1H-NMR (Figure 2.18A). The zeta potential of PEG-GNS was 




(-8.65 mV), which further confirmed the successful coating of PEG onto the GNS. 
The morphology of PEG-GNS was confirmed by TEM. The UV-Vis spectrum of 
PEG-GNS was recorded by UV-Vis spectrophotometer (DU®650 
Spectrophotometer, Beckman Coulter, USA), which showed an absorbance peak 
at 510 nm. 
Synthesis of 2-(pyridin-2-yldisulfanyl)ethyl acrylate modified GNS (PDA-
GNS) 
PDA-GNS was synthesized in a two-step procedure by conjugating PEG-
GNS with cysteamine first, followed by reacting with 2-(pyridin-2-yldisulfanyl)ethyl 
acrylate (PDA) through Michael addition reaction. Briefly, the PEG-GNS 
synthesized above was dispersed in 10 mL DI water, and then cysteamine (0.216 
mg in 40 µL H2O) was added. The mixture was kept stirring at room temperature. 
After 24 h of stirring, the reaction solution was loaded to a Millipore Centricon 
(MWCO=10,000 Da) and repeatedly washed by centrifugation to remove un-
reacted cysteamine. The successful conjugating of cysteamine was confirmed by 
zeta potential measurement, which showed a highly positive charge (+27 mV) on 
the GNS surface. The surface amine concentration was further measured by 
TNBSA assay, which also proved the successful replacement of PEG by 
cysteamine. The GNS concentration was determined by calculating UV-Vis 
absorbance. The result showed that there were around 1000 –NH2 groups 
located on the surface of each GNS. After that, PDA was conjugated to the GNS 
by reacting with amine groups via Michael addition reaction. Typically, 




(0.265 µL in 26.5 µL DMSO) was added, following the addition of PDA (0.459 mg 
in 50 µL DMSO). The ratio between –NH2 and PDA was optimized at 2:1 since a 
higher -NH2 to PDA ratio could easily result in GNS aggregation during the post-
purification process. The reaction mixture was purged with nitrogen and then 
kept at 50 °C for 24 h. The resulting PDA-GNS was precipitated in cold ether for 
three times to remove unreacted PDA and finally re-dispersed in 2 mL DI water. 
The successful conjugation of PDA was confirmed by UV-Vis spectrum (Figure 
2.18B). PDA-GNS showed a PDA characteristic peak around 375 nm after 
reacting with dithiothreitol (DTT). The PDA concentration of PDA-GNS was 
measured by DTNB assay, which proved that about 200 PDA was anchored to 
each GNS. 
Encapsulation of doxorubicin (DOX) into MSN 
To load DOX into MSN, DOX•HCl was firstly converted to its base form by 
mixing with triethylamine for 30 min. In a typical synthesis batch, 10 mg DOX was 
added to 18.6 mg MSN and the mixture was sonicated for 30 min to obtain a 
uniform dispersion. The mixture was stirred at room temperature for 24 h and the 
unloaded DOX was removed by washing with DI water twice. It was denoted as 
DOX@MSN. The loading efficiency of DOX was quantified by a 
fluorospectrometer (Beckman Coulter, DTX 880). Different loading of DOX can 
be simply tuned by changing the ratio between DOX and MSN. In this 






Fabrication of GNS decorated MSN (GoMe) 
GNS was grafted onto MSN through thiol-disulfide exchange reaction. 
MSN (200 μg in 200 μL) aqueous solution was added to 2 mL PDA-GNS 
aqueous suspension while stirring. The mixture was allowed to react at room 
temperature for 24 h, and then washed three times with DI water (Figure 2.1). 
The final product was collected by centrifugation. The size and morphology of the 
GoMe was determined by TEM. Cells were plated onto 12-mm glass coverslips 
in 24-well plates prior to drug treatment or transfection.  
Photothermal stability assay 
The repetitive laser irradiation experiments were carried out to test the 
photothermal stability of GoMe and gold-nanorod, which is critical for multiple 
photothermal treatments. Firstly, the concentration of GoMe and gold nanorod 
were adjusted to generate equal increment in temperature upon the same 
intensity of laser irradiation. The GoMe suspension was irradiated by the 808 nm 
laser for 10 min (Scorpius D-700 laser, 2.83 W/cm2). The temperature of the 
nano-suspension was monitored with a FLIR i7 thermal imaging camera and 
recorded every 30 sec. Both the GoMe and the GNR (maximum absorbance 
peak at 804 nm) were undergone 6 continuous laser irradiation cycles (10 min 
irradiation and 20 min cooling). The 7th irradiation was applied 24 h after the 6th 
cycle. The UV-vis spectra and TEM images were recorded to reveal the change 
during the repeating cycles. The photothermal stability of GoMe in reducing 
environment was further investigated by dispersing GoMe in DI water 




Laser irradiation triggered release of GoMe 
To evaluate the responsiveness of GoMe to NIR light, 20 μL of GoMe 
containing 4 μg of DOX was diluted with 250 μL DI water. The GoMe suspension 
was incubated at 37 °C to carry out the release study. GoMe nano-suspension 
was centrifuged at 1, 2, 4, 6, 8, 12, and 24 h at 16,000 rcf for 10 min to separate 
released DOX from GoMe particles. After that, the same amount of fresh medium 
was added to re-suspend the GoMe pellet. At 24 h post the start of the releasing 
experiment, the GoMe suspension was irradiated by an 808 nm laser for 10 min 
(2.83 W/cm2). Sample was collected immediately by centrifugation after the 
irradiation. The sample was then incubated at 37 °C followed by sampling twice 
(at 1 h intervals), and then incubated till the next 24 h point. The whole release 
process was continued for 4 days. The amount of DOX in the supernatant was 
determined by a fluorospectrometer (Beckman Coulter DTX 880, excitation: 485 
nm and emission: 545 nm).  
GNS decorating density effect assay 
The effects of different GNS density on a single MSN were explored by 
examining the product of the reaction between GNS and MSN at different time 
intervals. The reaction was carried out in a transparent 2.5 mL 
spectrophotometer cuvette. The UV absorbance spectrum was recorded directly 
as the reaction proceeding, while the photothermal converting capacity of the 
mixture was examined by irradiating the diluted reaction mixture with the 808 nm 
laser. The reaction was also monitored by observing the morphology of GoMe 




Cellular internalization assay 
The A 2058 cell, a human melanoma cell line,  was cultured in Dulbecco’s 
modification of eagle medium (Corning, Manassas, VA) supplemented with 10% 
FBS and 1% penicillin-streptomycin (Life Technology, Grand Island, NY) at 37 °C 
in 5% humidified CO2 atmosphere. Cells were seeded in 35 mm petri dishes with 
a density of 200,000 cells/petri dish. After overnight incubation, 5 μM 
DOX@GoMe was added and continued incubation for another 3 h. Cells were 
washed once with complete medium and then stained with Hoechst 33342, 
followed by confocal microscopy imaging (LSM 700, Zeiss) and dark field 
microscopy imaging (Leica DM6000 M). 
Live/dead cell assay after photothermal therapy 
The photothermal effect of GoMe in cell culture medium was evaluated in 
a 96-well plate. GoMe of different concentrations were added to each well 
containing 100 μL complete medium. The resulting GoMe nano-suspension was 
irradiated with NIR laser (808 nm, 2.83 W/cm2) for 10 min at predesigned time 
intervals and its temperature was monitored with a FLIR i7 thermal imaging 
camera and recorded every 1 min. To visualize the effect of laser irradiation on 
the cell death, Live/Dead cell imaging kit (Molecular Probe®) was used. 10,000 
cells were seeded in 96-well plate and incubated at 37 °C in 5% CO2 overnight. 
Blank GoMe (1 μM or 5 μM) was added and incubated for 2 h. For GoMe treated 
groups, an 808 nm laser was used to irradiate cells for 10 min, while others had 
no laser treatment. Cells were kept in the incubator for 2 h and stained with 




was imaged from 5 different positions (top, bottom, left, right and middle) with 
fluorescent microscopy (Axiovert 200, Carl Zeiss) under 20 × magnification using 
FITC and Texas red channels. 
Cytotoxicity assay 
For cell viability assays, A2058 cells were seeded in a 96-well plate 
(10,000 cells/well) and incubated at 37 °C in 5% CO2 overnight. DOX, MSN, 
DOX@MSN, GoMe, and DOX@GoMe were diluted with complete medium to 
achieve targeted concentrations. After 24 h of incubation, GoMe and 
DOX@GoMe irradiation groups were exposed to 808 nm laser irradiation for 10 
min. The cells were allowed to grow overnight and then added with MTT reagent. 
MTT stop solution was added after 4 h of incubation to dissolve MTT formazan 
crystals. The optical density of the medium was measured using a microplate 
reader (ELX808, Bio-Tech Instrument, Inc.) at λ = 595 nm. 
64Cu Radiolabeling of GoMe Nanoparticle 
DOTA was conjugated onto GoMe nanoparticles by adding Maleimide-
mono-amide-DOTA (20 mM, 50 μL in DMSO) to 1 mg GoMe aqueous solution (1 
mg/ml). After 6 h of reaction at room temperature, the free DOTA was separated 
from GoMe by centrifugation and washing with DI water twice. The resulting 
pellet was re-suspended in 1 ml DI water. GoMe nanoparticles were further 
radiolabeled by 64Cu via the DOTA chelator as previously reported 58. The 
radiolabeling was accomplished by addition of 1.0-1.5 mCi of 64CuCl2 in 0.1 M 
HCl (University of Wisconsin) to a mixture of 50 μL 0.1 N ammonium acetate (pH 




incubation at 37 °C for 30 min. The radiolabeled nanoparticles were collected into 
300-400 μL of phosphate buffered saline by centrifugation. 
Animal model establishment 
All experiments were carried out under protocols approved by the 
Institutional Animal Care and Use Committee. Our mouse model was based on 
one reported by Berr’s group.58 Female FVB mice (Jackson Laboratory) aged 6-8 
weeks received weekly intraperitoneal (IP) injections of 1 mg urethane/g body 
weight dissolved in sterile 0.9% NaCl. Twenty weeks after the initial urethane 
injection, MRI was used to verify lung tumor presence. PET imaging was 
performed when at least one lung tumor reached 1.5 mm in diameter. 
MRI and PET Animal imaging 
Twenty-four weeks after urethane treatment, lung tumor bearing mice 
were first imaged on a 7 Tesla ClinScan MRI system (Bruker BioSpin 
Corporation, Billerica, MA), Inc., Palo Alto, CA). MRI were acquired with a 
cardiac and respiratory gated, multi-slice, spin-echo sequence developed in our 
lab with the following parameters: field of view 30 mm, effective matrix = 192 × 
192 zero-filled to 256 × 256, slice thickness 0.7 mm, TR was a function of the 
breathing cycle and averaged to about 1 second. The TE was 11ms, the number 
of averages was 4, and the number of slices was 15 with a gap equal to 0.7mm 
between slices to avoid crosstalk. The slice stack was moved by 0.7mm and 15 
other interleaved slices were acquired.  Gadolinium-DTPA contrast agent 
(Magnevist; Bayer Schering Pharma, Berlin, Germany) was injected at a dose of 




injected with 64Cu-labeled GoMe nanoparticles via the lateral tail vein. Each 
mouse received 500-750 μCi of 64Cu for a total volume of 150-200 μL. Mice 
were imaged using a Focus 120 PET scanner (Positron Emission Tomography) 
(Siemens, Knoxville, TN) at 6 h and 20 h post administration. During the 40 min 
PET acquisition, anesthesia was maintained using 1.25% isoflurane in O2 inhaled 
through a nose cone. Heart rate, respiration, and rectal temperature were 
monitored (SAII, Stony Brook, NY). PET data were reconstructed using OSEM 
algorithm with 2 iterations and 12 subsets followed by MAP algorithm (18 
iterations). The reconstructed image (not corrected for attenuation) was 
composed of 95 axial slices of thickness 0.79 mm with an in-plane voxel 






Figure 2.1 Schematic illustration of the fabrication of GoMe. (A) The preparation 
scheme of GoMe. (B-D) TEM images of MSN, PEG-GNS, and GoMe 
nanoparticles. Scale bars are 50, 10, and 50 nm in (B), (C), and (D), respectively. 















Figure 2.3 SEM image of GoMe. Image was acquired with a Zeiss Ultra Plus 



































Figure 2.8 Reaction monitoring of GNS conjugation to MSN with UV and TEM. 
The UV-Vis spectra of GNS, MSN, and their mixture after 12 and 24 h of reaction 
(A), as well as their photothermal heating curves upon 10 min of 808 nm laser 
irradiation (2.83 W/cm2) (B). TEM images of GoMe formed after 2 h (C), 12 (D), 







Figure 2.9 The photothermal effect of GoMe at different concentrations. Nano-







Figure 2.10 Real-time temperature elevation of GoMe and GNR nano-
suspensions during 7 cycles of NIR irradiation. GoMe and GNR were irradiated 
with an 808 nm NIR laser for 10 min (2.83 W/cm2) and then cooled down for 20 







Figure 2.11 The photothermal effect of GoMe in medium with or without GSH. 
Nano-suspension of GoMe was irradiated by the 808 nm laser (2.83 W/cm2, 10 







Figure 2.12 The UV-Vis spectra and TEM images of GoMe and GNR changed 
due to repeated photoirradiation. The UV-Vis spectra (A) and TEM images of 
GoMe (C, D), and the UV-Vis spectra (B) and TEM images of GNR (E, F). TEM 
images of GoMe before laser irradiation (C) and after 5 cycles of irradiation 
induced heating/cooling (D). TEM images of GNR before laser irradiation (E) and 
after 5 cycles of irradiation induced heating/cooling (F). Red arrows indicate 








Figure 2.13 The release kinetics of GoMe in different conditions. In plain PBS or 
PBS supplemented with GSH (A) and under the trigger of NIR irradiation (B). The 
red arrows indicate the time points when the irradiation (10 min, 2.83 W/cm2) was 







Figure 2.14 The uptake of DOX@GoMe by confocal and dark-field microscopy. 
The confocal (A-F) and dark-field (G-J) images of A2058 cells co-cultured with 
DOX@GoMe. Cells in A-C, and G-H were control. Cells in D-F, and I-J were 
treated with DOX@GoMe. Images H and J were collected in dark-field mode. 







Figure 2.15 The real-time medium temperature during NIR laser irradiation of 
different GoMe concentrations. GoMe concentration was calculated based on 






Figure 2.16 Cytotoxicity of DOX@GoMe coupled with NIR irradiation. The 
fluorescent images of live/dead cell assay (A-C) after NIR irradiation and the 
cytotoxicity of DOX@GoMe coupled with NIR irradiation (10 min, 2.83 W/cm2) 
(mean ± SD, P < 0.05 *; P < 0.01 #). Cells in A, B, and C were treated with blank 
medium, blank GoMe, and GoMe coupled with NIR irradiation, respectively. 








Figure 2.17 MRI and PET animal imaging. (A) Four contiguous MRI transverse 
images, (B-D) PET images of 3 tumors in the lung of mouse received 
radiolabeled GoMe. Tumors are indicated by yellow arrows in (A). (B) PET 
images of contiguous slices in transverse acquired 6 h post administration. 
Tumors are indicated by green arrows in (B). Whole body PET images acquired 6 







Figure 2.18 1H-NMR of PEG-GNS and the UV-Vis spectra of PDAGNS. (A) 1H-





Sigma receptors targeted GoMe for cancer photothermal therapy and 
photodynamic therapy  
ABSTRACT 
Although various nanocarriers have been developed to treat cancer, how 
to use a multifunctional nano-carrier to treat cancer patients more efficiently and 
personalized remains to be a challenge. Here, we present a gold nanoparticle 
conjugated mesoporous silica nanoparticles hybrid (GoMe) as a carrier for Pc 4. 
The results show that GoMe actively targets sigma 2 receptors overexpressing 
cancer cells, and rapidly releases Pc 4 inside cancer cells upon the high reducing 
intracellular environment or external laser irradiation. Pc 4 coupled with 660 nm 
laser irradiation generates singlet oxygen in the mitochondria of oxygen-rich 
tumor tissues and initiates the subsequent cell apoptosis or necrosis, and the 
remaining tumor cells in hypoxia regions are killed immediately upon subsequent 
808 nm laser irradiation toward GoMe. Our study shows that GoMe is superior in 
inhibiting cross-resistance with any other chemotherapy, and more importantly, it 
is highly efficient in eradicating tumors in UMSCC 22A xenograft mice model. 
Our design can serve as the site specific anti-cancer therapy and be a promising 





Photodynamic therapy (PDT) is a clinically approved effective strategy 
against various malignant cells.59 Three elements are essential in the application 
of PDT, light, photosensitizer (PS) and oxygen. It’s a two-stage reaction process: 
Firstly, PS is applied in the disease foci and exposed to light at a specific 
wavelength corresponding to the type of PS. Then, energy transferred from the 
light by PS will initiate a series of consequences at the presence of oxygen which 
will eventually cause the cell apoptosis or necrosis, systemic immune reaction 
and destruction of microvasculature. The major advantage of PDT is its unique 
oxygen-dependent tumor cells eradiation mechanism, which is unlikely to 
generate cross-resistance with other therapies.60 It is especially beneficial for the 
tumor that is inoperable. Another advantage of PDT relies on its boosting 
systemic immunity function.61 Until now, there are over 200 clinical trials using 
PDT in the field of skin melanoma, head and neck, non-small lung, bladder, 
ovarian, and brain cancers.62 
However, the application of PDT in anticancer is greatly impaired by the 
requirement for the rich oxygen environment, which is not always available in 
solid tumor microenvironment. A solid tumor is composed with mild to severe 
hypoxia regions as well as re-oxygenation regions. With the dynamic oxygen flow 
occurring within these tumor areas through the chaos position of newly 
generating vasculatures, it can greatly reduce therapeutic potential of PDT.63 In 
addition, PDT induced the destruction of tumor vasculature will cause oxygen 




it’s crucial to deliver and maintain a therapeutic level of PS in all tumors and to 
reduce its liability on the oxygen level. 
Abundant trials have been performed by either modulating the light 
delivery or applying an excessive oxygen during PDT.64 In order to achieve a 
higher oxygen level in tumor foci, patients who were receiving PDT were 
maintained under the hyperbaric oxygen condition. The combination of PDT and 
hyperbaric oxygen supply elongates the mean survival time for patients with 
squamous cell carcinoma or adenocarcinoma.64c Instead of continuous 
illumination, disrupting illumination in two fractions with refractory interval was 
practiced on the rats bearing U87 human primary glioblastoma tumor and results 
showed a severe necrosis in tumor tissue, indicating a better therapeutic 
effect.64b Nanomedicine was developed to overcome these challenges, and 
polymer based nanoparticles,65 carbon nanodots,66 and superparamagnetic iron 
oxide nanoparticle67 were good candidates to deliver PDT. More recently, a co-
doped nanoparticle was developed to co-deliver PS H2TPyP and 
chemotherapeutic agent curcumin to treat A549 human alveolar adenocarcinoma 
xenograft mice model. They successfully reduced the tumor volume by 74% 
through daily injection of the nanoparticle.68 
Here we developed a new nanocarrier that combined PDT and 
(photothermal therapy) PTT by loading Pc 4 into gold nanoparticle-mesoporous 
silica nanoparticle hybrid (GoMe). The GoMe was able to efficiently and 
specifically enter cancer cell through sigma 2 receptor mediated endocytosis and 




and completely eradicate cancer cells with minimized side effects. Intracellular 
GSH level  or low pH environment in lysosome would trigger the release of Pc 4, 
and upon the irradiation of a 660 nm laser, cells containing Pc 4 were killed 
through either ROS induced cell apoptosis or necrosis. Cells in the hypoxia areas 
survived from PDT were immediately burned by 808 nm photoirradiation. We first 
tested the physical properties and biocompatibility of GoMe in physiological 
environment, and examined the dual responsiveness of Pc 4 GoMe to 
intracellular high redox potential environment and external photoirradiation. 
Secondly, we elucidated the subcellular targets of MBA Pc 4 GoMe and its 
mechanism of producing reactive oxygen species. Last, we validated the 
synergistic efficacy of PDT and PTT of these nanoparticles in UMSCC 22A head 
and neck bearing xenograft mice. 
Results and discussion 
Synthesis of MBA PC 4 GoMe 
Silicon phthalocyanine Pc 4 is used to treat squamous cell carcinoma and 
skin cancer in various clinical trials. Pc 4 GoMe was prepared by conjugating Pc 
4 loaded MSN with gold nanospheres. Pc 4 loaded MSN was evenly covered by 
PEG-SH (Mw=3400) stabilized gold nanosphere.69 TEM revealed that the final 
diameter of GoMe reached 50 nm (Figure 3.2B). The UV absorbance of Pc 4, 
PC 4 MSN or Pc 4 GoMe appeared at 680 nm (Figure 3.2F), suggesting that the 
efficient Pc 4 based PDT should occur upon a 660 nm laser irradiation.  
To conjugate targeting moiety to Pc 4 GoMe, 4-methoxybenzoic acid 




the amine in polymer NH2-PEG-Mal and the carboxylate group of MBA as shown 
in Figure 3.1B. The successful conjugation of MBA to SH-PEG-Mal was 
confirmed by 1H-NMR as shown in Figure 3.2E, where the existence of MBA was 
evidenced by the peak at 7.8 ppm (2H). The quantification of MBA conjugation 
efficiency was tested by TNBSA assay. By comparing the available free amine in 
MBA-polymer PEG-Mal to that in NH2-PEG-Mal, we concluded that 85.62% of 
the free amine in NH2-PEG-Mal was replaced by MBA. 
MBA-Pc 4 GoMe didn’t exhibit an increased size comparing to Pc 4 GoMe 
according to TEM and SEM, but DLS showed a slight increase (about 24 nm) 
(Figure 3.2B-D and 3.3A). Comparing with Pc 4 GoMe, the surface charge of 
MBA-Pc 4 GoMe was decreased from -1.13 mV to -2.93 mV (Figure 3.3A). 
Photothermal response of Pc 4 GoMe  
To evaluate the photothermal response of Pc 4 GoMe, we tested the 
photothermal capacity of Pc 4 GoMe at different concentrations. The absorbance 
at 450 nm was used to represent Pc 4 GoMe concentration, as it is an indicator 
for the density of gold on the surface of MSN.70 As shown in Figure 3.3B, the 
absorbance at 450 nm positively correlated with the concentration of Pc 4 GoMe. 
When the OD at 450 nm was at 0.08, it was enough to generate the energy that 
can heat the surrounding aqueous solution up for 14.2 °C, while with the OD 
increasing to 0.65, it was able to reach 63 °C after 10 min irradiation (Figure 
3.3C). The heat transducing efficiency was 28% based on Figure 3.3D. Neither 
water, MSN, nor gold nanoparticle themselves were able to generate enough 




as we previously proved, is a thermal stable nano-carrier that can maintain its 
integrity upon intensive and repetitive irradiation.69 If the cancer cells have not 
been completely eradicated in any scenario, a repeatable PTT can be applied 
without any additional dose.  
Colloidal stability and release behaviors of Pc 4 GoMe  
The strong advantages of this system lie in its colloid stability during 
circulation and responsiveness to intracellular signal and external NIR irradiation. 
The premature release of Pc 4 in blood circulation or in the undesirable tissue 
would lead to decreased bioavailability for target site and  increased skin 
sensitivity toward light.71 Our design can avoid this risk by sealing the Pc 4 inside 
the pore channels of MSN during circulation. Once it enters the targeting cancer 
cells, Pc 4 can be released by two mechanisms: firstly, intracellular high redox 
potential partially cleaves the disulfide bond and loosen gold on the surface of 
MSN, which induces release of Pc 4. Second, Pc 4 release can also be switched 
on by NIR irradiation at 808 nm on GoMe, where an intensive heat will be 
generated and followed by Pc 4 release. Figure 3.4A showed that with the 
addition of 10 mM GSH in medium, Pc 4 GoMe doubled its release at the first 
hour of incubation and released over 50% of its loading by the end of 24 h. In 
addition, it was confirmed that Pc 4 GoMe showed a complete release of Pc 4 
after laser irradiation at 808 nm for 10 mins, indicating that Pc 4 is able to 





Colloidal stability is an important indicator for the destiny of administered 
NPs in vivo, in which aggregated nanoparticles will alter drug pharmacokinetics, 
toxicity and biodistribution. We used several media to estimate Pc4 GoMe 
stability, including different concentrations of serum containing DMEM media and 
PBS considering of the potential effects of ion strength and protein adsorption. 
Pc 4 GoMe at the concentration of 100 µg/mL in 10% FBS containing DMEM 
media showed no significantly increase in hydrodynamic size for up to one week 
(Figure 3.4D). Meanwhile, we also investigated the release of Pc 4 during this 
period and found that in 10% serum containing medium at 37	°C, Pc 4 only 
released less than 10% of its loading by the end of 48 h. In 50% serum medium, 
Pc 4 would only release around 30% at the end of 48 h incubation (Figure 3.4C). 
Therefore, Pc 4 GoMe was not prone to aggregate in circulation and showed an 
excellent serum compatibility. 
Reactive oxygen species  
PS can produce ROS through type I and type II reaction. For Pc 4, it 
mainly goes through the type II reaction. Instead of directly producing hydroxyl 
and superoxide radicals, it reacts with tissue oxygen and produces singlet 
oxygen upon excitation.72 We evaluated the capability of PC 4 GoMe in 
generating singlet oxygen using both 9,10-dimethylanthracene (DMA) and SOSG 
assays.73  
DMA reacts with 1O2 (singlet oxygen) and forms non-fluorescent 9,10-
endoperoxide.74 Figure 3.5A revealed that the fluorescence of DMA decreased 




decrease of DMA fluorescence at 432 nm was proportional to the photoirradiation 
duration. Longer co-incubation with GSH (16 h) was able to diminish the 
fluorescent intensity by 61.4%, almost reaching the activity of free Pc 4.  
To further study the singlet oxygen generating capacity of the 
nanoparticle, fluorescently-quiescent SOSG which can react specifically with 
singlet oxygen and produce a fluorescent SOSG-endoperoxide molecules was 
employed. Figure 3.5B-E showed the Pc 4 generated the highest singlet oxygen 
level after photoirradiation, and Pc 4 GoMe generated 73% of singlet oxygen 
compared with free Pc 4. However, 24 h of GSH pretreatment boosted the singlet 
oxygen generating capacity of Pc 4 GoMe to 90% of that of free Pc 4. 
As evidenced from the above in vitro results, Pc 4 GoMe was nearly as 
effective as free Pc 4 in generating singlet oxygen after GSH treatment. We 
further evaluated the intracellular oxygen species levels induced by Pc 4 GoMe. 
As we discussed earlier, the intracellular GSH level is significantly higher than 
that of the extracellular matrix. It is expected that after the internalization of 
nanoparticles, GSH would trigger the release of Pc 4, which can generate singlet 
oxygen upon photoirradiation. Since SOSG itself is a weak photosensitizer, 
various controls were employed to exclude the effect of either SOSG, NIR or Pc 
4 themselves. Without NIR, neither Pc 4 nor Pc 4 GoMe could generate 
detectable signals of oxidized SOSG. In response to NIR, they generated a 
strong green fluorescence indicating the abundant existence of intracellular 
singlet oxygen. In addition, there was no significant difference among the Pc 4, 




Cellular uptake of MBA Pc 4 GoMe 
Sigma 2 receptors were overexpressed in UMSCC 22A cells. Therefore, 
MBA with high affinity to sigma 2 receptors was chosen as the targeting moiety 
for UMSCC 22A cells.32b, 75 In our study, the targeting moiety MBA was 
conjugated on the surface of nanoparticles, which ensures its availability when 
nanoparticle was exposed to cells. To investigate the internalization efficiency of 
MBA Pc 4 GoMe, UMSCC 22A cells were treated with free drug or GoMe or MBA 
GoMe and examined with FACS and confocal microscopy. Figure 3.7A showed 
that longer co-incubation led to an increased internalization of Pc 4 into cells at 
37 °C. Both Pc 4 GoMe and MBA Pc 4 GoMe treatments showed a better uptake 
than free Pc 4. MBA Pc 4 GoMe showed the highest uptake, where over 40% of 
Pc 4 was internalized inside cells compared with free Pc 4 (Figure 3.7A-C).  
Previous research showed that hydrophobic PS enters cells by the 
incorporation into lipoproteins such as low density lipoproteins (LDL) and 
followed by LDL-receptors dependent endocytosis76 and MBA Pc4 GoMe enters 
cell through sigma 2 receptor mediated endocytosis. Since the endocytosis is an 
energy dependent process, a lower temperature would reduce the uptake of Pc 4 
or Pc 4 GoMe.77 We compared the uptake behaviors of these nanoparticles at 4 
°C and observed a significantly decrease of Pc 4 uptake (Figure 3.7D-F). The 
uptake of MBA Pc 4 GoMe group was reduced mostly by the lower temperature, 





Confocal microscopy was employed to study the role of MBA in MBA Pc 4 
GoMe internalization. As shown in Figure 3.7G, with the addition of free MBA, 
the total Pc 4 uptake was significantly inhibited. It is suggested that the free MBA 
was able to partially block the accessibility of sigma 2 receptors, which 
subsequently interfered the interaction of MBA Pc 4 GoMe with the cells and 
negatively impacted its uptake.  
Characterize PDT of Pc 4 GoMe for UMSCC 22A cells 
We have shown that MBA Pc 4 GoMe enters the cells more efficiently 
than Pc 4 GoMe and Pc 4. We then tested whether enhanced uptake of Pc 4 
resulted in better photodynamic therapy. After Pc 4 entered cells, it primarily 
located in the mitochondria 2 h after treatment.78 PC 4 PDT induces cell 
apoptosis and necrosis by photodamaging two antiapoptotic proteins Bcl-2 and 
Bcl-Xl. These proteins interacts with mitochondrial permeability transition pore 
complex and governs mitochondrial death pathway partially through controlling 
cytochrome C release. To test whether Pc 4 GoMe can enter mitochondria, 
confocal microscopy was applied to track Pc 4 intracellularly (Figure 3.8A). We 
compared the overlap of Pc 4 and mitochondria channels in the treatment of Pc 
4, Pc 4 GoMe or MBA Pc 4 GoMe, and found that the orange signals in both Pc 4 
GoMe and MBA Pc 4 GoMe were significantly stronger than that in free Pc 4 
treated cells. Among these groups, MBA Pc 4 GoMe showed the highest 
accumulation in mitochondria. Since the loss of mitochondrial membrane 
potential (ΔΨm) is a critical step for cytochrome C release,79 we monitored the 




fluorescent intensity to green fluorescence intensity. JC-1 dye can selectively 
enter mitochondria, and exist in either aggregation or monomer form depending 
on the health status of mitochondria: If the mitochondria are in the healthy form, 
mitochondrial membrane potential will maintain a high level and JC-1 stays in 
aggregation form and displays red fluorescence; otherwise, JC-1 will be in form 
of monomer and show green fluorescence. After PDT for cells treated with 1 µM 
Pc 4, the ratio of JC-1 aggregation form to JC-1 monomer form decreased from 
14.81 to 5.64 in free Pc 4 treated cells, while this ratio for cells treated with Pc 4 
GoMe dropped to 9.84, indicating that mitochondria was damaged in response to 
PDT (Figure 3.8B and C). 
Synergistic effects of PDT and PTT on the viability of cancer cells 
To validate the direct cytotoxic effect of PTT and PDT, a live/dead staining 
assay was carried out on cells after exposure to PDT, PTT, or the combination of 
PDT and PTT. The ethidium homodimer-1 in the kit, an indicator of loss of 
plasma membrane integrity, can distinguish between dead (Red) and living 
(Green) cells. Figure 3.9A-H represented the acute consequence of PDT and 
PTT on UMSCC 22A cells that had been incubated with Pc 4, Pc 4 GoMe or 
MBA Pc 4 GoMe for 3 h. The PDT and PTT were administered by irradiating cells 
with a 660 nm laser and the 808 nm laser, respectively. Neither control cells nor 
free Pc 4 treated cells show noticeably cell death in response to the PDT or the 
combination of PDT and PTT (Figure 3.9A and B). Pc 4 GoMe and MBA Pc 4 
GoMe treated groups also did not increase the cell death in response to PDT 




generate enough pro-apoptotic factors.80 PTT can kill cancer cells more rapidly 
as shown in Figure 3.9G and H. Pc 4 free drug did not show dual laser induced 
cytotoxicity, while GoMe eradicated cancer cells more efficiently in response to 
dual laser suggesting a PTT and GoMe dependent mechanism for cell killing. 
To further evaluate the synergistic effects of PDT and PTT in Pc 4 GoMe, 
we tested the PDT/PTT effect on UMSCC 22A and A 2058 cells using MTT cell 
viability assay. In this experiment, skin cancer and head and neck cancer cells 
were chosen due to the practical clinical application of Pc 4 as mentioned earlier. 
The cytotoxicity of Pc 4 GoMe or MBA Pc 4 GoMe on A 2058 or UMSCC 22A 
without any photoirradiation was negligible at Pc 4 concentration ranging from 25 
to 500 nM, suggesting low side effects and high compatibility (data not shown). 
With the PDT alone, Pc 4 killed 64% UMSCC 22A cells and 59% of A 2058 cells 
at 500 nM under 200 mJ/cm2 laser irradiation. At the same Pc 4 concentration, 
Pc 4 GoMe killed about 30% cells, which was less effective compared to free Pc 
4. MBA Pc 4 GoMe showed similar cell killing effect to free Pc 4 in UMSCC 22A 
(Figure 3.9I) and A 2058 cells (Figure 3.9K). Taking together the enhanced 
cellular uptake of MBA Pc 4 GoMe, we can conclude that MBA induced the 
accumulation of MBA Pc 4 GoMe inside sigma 2 overexpressing cancer cells and 
led to stronger PDT effect. 
Next, we tested if the combination of PDT and PTT shows synergistic 
effect and if the sequence of two therapies matters in killing cancer cells. Figure 
3.9J showed that at low concentration, Pc 4 GoMe treated cells showed almost 




able to kill 38% of cancer cells. But if PDT was applied first and followed by PTT, 
Pc 4 GoMe dramatically increased its efficacy. Surprisingly, MBA Pc 4 GoMe 
was able to kill around 95% of cells even at low concentration if cells were first 
receiving PDT followed by PTT (Figure 3.9J). In A 2058 cells, we only test the 
PTT followed by the PDT therapy (Figure 3.9L). With this combination MBA Pc 4 
GoMe was able to achieve an 83% of cell death, which was superior to Pc 4 
GoMe or Pc 4. Such cytotoxicity results clearly proved the advantages of 
combination of PDT and PTT in treating various cancer cells, especially at the 
sequence of application with PDT followed by PTT. We speculate that when 
applying PTT first, GoMe generates high temperature that may exclude some 
oxygen out of the cancer cell environment, thus greatly reduces of PDT effect. 
The sequence that PDT followed by PTT can cause remarkable cell death due to 
the direct interaction of heat with PDT affected the tumor cells. In addition, if 
applied in vivo, it is expecting that the sequence is more important as severe 
tumor hemorrhage would occur due to the initial heat from PTT which hampers 
the efficacy of PDT.  
In vivo antitumor efficacy 
To evaluate the in vivo antitumor effect of GoMe, we divided UMSCC 22A 
bearing nude mice into 6 groups: saline, Pc 4 with PDT, Pc 4 GoMe with PDT, 
MBA Pc 4 GoMe with PDT, Pc 4 GoMe with dual photoirradiation and MBA Pc 4 
GoMe with dual photoirradiation. All the treatments were well tolerated as mice 
bodyweight remained the same throughout the whole period (Figure 3.10A). 




beginning of the treatment. Comparing to the control, the mice treated with Pc 4 
GoMe or MBA Pc 4 GoMe alone with PDT slowed the growth of tumor, indicating 
an inhibited tumor progression (Figure 3.10 B-E). It has been reported that tumor 
that survived from PDT will start to regrow in 4-5 days after PDT or 6-7 days after 
the combined PDT and hyperthermia therapy.81 Surprisingly,  Pc 4 GoMe or MBA 
Pc 4 GoMe coupled with dual laser irradiation completely eradicated the tumor, 
and tumors failed to recur over 28 days post treatment, (Figure 3.10B and C). 
There were no significant difference between MBA Pc 4 GoMe and Pc 4 GoMe 
after dual laser irradiation. Figure 3.10C showed that Pc 4 alone with PDT, MBA-
Pc 4 GoMe with PDT, and Pc 4 GoMe with PDT achieved 64.4%, 91.04%, and 
58.56% tumor growth inhibitory effect, respectively. In contrast, MBA-Pc 4 GoMe 
coupled with dual laser treatment achieved over 99% tumor growth inhibitory 
effect.  
Histology were carried out on the tumors (Figure 3.11A) and livers 
(Figure 3.11B) of the mice with different therapies. Tumor tissues were isolated 
and examined with H&E staining. There was clear necrosis or apoptosis sign in 
the tumor tissues from the dual laser treatment compared to the control, and we 
did not observe liver damage or inflammation lesion, suggesting the liver function 
was not hampered by MBA Pc 4 GoMe.  
CONCLUSION 
For currently available cancer therapy, PDT is widely used as an auxiliary 
strategy to enhance chemotherapy or radiotherapy. As early as 1988, there are 




together would lead to an enhanced antitumor effect in murine model.82 However 
the drawbacks of PDT in heavily relying on oxygen level and inability to eradicate 
cancerous cells failed to prevent the recurrence of tumor. Recently studies have 
been practiced to combined PDT with PTT using various nanocarriers to achieve 
higher potency against cancer cells. The synergistic combination can be 
achieved by co-administering gold nanoshell together with porphyrin,83 or by 
combination of chlorin e6 and poly(dopamine).84 Despite of the progress, more 
effects are needed to enhance the synergistic effect of PDT and PTT. In this 
study, we have developed a sigma 2 receptor targeted Pc 4-loaded nano-carrier 
for photodynamic therapy and photothermal therapy. The PDT effect can be 
enhanced by regulating the PS distribution and accumulation inside cancerous 
cells. With the combination of PTT, the cancer cells were killed over 95% in vitro 
and in vivo experiment showed complete cancer cell eradiation after the dual 
laser therapy. Additionally, the active targeting to sigma 2 receptor 
overexpressing cancer cells further amplify the therapeutic effect. This nano-
carrier is good in relieving the heavy burden of PDT on oxygen levels and will not 
confer any cross-resistance if any other adjuvant therapy is applied.  
MATERIALS AND METHODS  
Materials 
Terraethylorthosilicate (TEOS), (3-mercaptopropyl)trimethoxysilan) 
(MPTMS), hexadecyltrimethyl ammonium bromide (CTAB), sodium hydroxide 
(NaOH), pluronic®F-127, 9,10-dimethylanthracene (DMA), tween-80, Ammonium 




disulfide, triethylamine (TEA), glutathione (GSH), 4-mercaptobenzoic acid (MBA), 
thiazolyl blue tetrazolium bromide (MTT) and sodium borohydride (NaBH4) were 
purchased from Sigma-Aldrich. PEG2000-SH was purchased from Laysan Bio. 
Maleimide -PEG-NH2 (Mw=3400) was purchased from Creative PEGworks. 
Ethanol and acetic acid were acquired from Fisher Scientific. Silicon 
phthalocyanine Pc 4 was obtained from NIH. Live and dead staining kit, SOSG 
was obtained from Thermofisher Scientific. JC-1 Mitochondrial Membrane 
Potential Assay Kit was purchased from Cayman chemical. 
Transmission Electron Microscopy (TEM) was conducted on a Hitachi 
H8000 at an acceleration voltage of 200 KV. Scanning electron microscopy 
(SEM) was conducted on a Zeiss Ultra plus FESEM at 6 KV. UV-vis spectrum 
was obtained with a DU UV/Vis 650 (Beckman). 1H-NMR was conducted in a 
Bruker Avance III HD 300. Fluorescent Microscopy images were obtained with an 
Olympus IX81 fluorescence microscopy. Confocal microscopy images were 
obtained with a Carl Zeiss LSM 700. Flow cytometry was conducted in a 
Beckman coulter FC500 flow cytometer. 
Synthesis of PC 4 loaded GOME 
MSN and gold nanoparticles were synthesized as described.69 Pc 4 was 
dissolved in DMSO at 10 mg/ml and mixed with MSN at 5/100 weight ratio. After 
the overnight stirring, un-encapsulated Pc 4 was removed by centrifugation and 
followed by twice washing with H2O. To conjugate Au nanosphere to MSN, 800 
µg of Pc 4 MSN was reacted with 2 nmol AU-PDA through thiol-disulfide bond 




H2O twice. PC 4 loading content was determined by fluorescent plate reader (M2, 
Molecular device) with excitation at 630 nm and emission 670 nm. The total 
loading P4 amount was determined by triple washing in DMSO to completely 
dissolve the encapsulated drugs with extensively sonicating. 
Synthesis of polymer SH-PEG-MBA 
MBA was conjugated with Mal-PEG-NH2 through EDC/NHS reaction. MBA 
(5 mg in 0.4 mL DMSO) was added to EDC/NHS solution (2 equiv of MBA, 0.1 M 
MES pH 6) and allowed for activation at r.t for 30 mins. Mal-PEG-NH2 (20 mg, 
5.71 µM) was dissolved in DMSO/ pH 7.4 buffer. MBA activated solution (1.74 
mg) was added to Mal-PEG-NH2 solution above. The reaction was carried out at 
r.t for 24 h. Crude product was purified by dialysis for 24 h in DMSO followed by 
dialysis in ddH2O for 24 h with a dialysis membrane (MWCO=1000 Da). The final 
product was collected through lyophilization and stored at -20 ºC until use. 
Polymer conjugation was confirmed by 1H-NMR using CDCl3 as the solvent and 
the reaction yield was quantified with TNBSA assay by calculating the reduced 
amine in the polymer. 
Preparation of PC 4 GOME coated with SH-PEG-MBA 
PC 4 GoMe was well dispersed in ddH2O at 1 mg/ml. SH-PEG-MBA was 
dissolved in H2O at the concentration of 2 mg/ml and mixed with PC 4 GoMe 
(1:2, w/w). The mixture was stirred and reacted for 24 h at r.t. MBA conjugated 
PC 4 GoMe (MBA-PC 4 GoMe) was isolated from unreacted SH-PEG-MBA by 
centrifugation followed by washing with H2O twice. Final product was dispersed 




Characterization of MBA PC 4 GoMe 
GoMe was diluted at the concentration of 20 µg/ml in H2O and 3 drops of 
the suspension was loaded onto a 200-mesh copper grid coated with formvar. 
Air-dry the grid and analyzed with TEM (Hitachi) using 200 K acceleration 
voltage. GoMe was suspended in ethanol and drop on the silicon wafer. Air-dry 
the wafer and analyzed with SEM with 6 KV under 200,000X magnification. The 
UV/vis spectrum was recorded with a DU650. The size was determined with 
dynamic light scattering and surface charge was recorded with a Malvern Nano-
ZS Zeta Sizer.  
Photothermal response 
Pc 4 GoMe was diluted to a serial of concentrations with PBS and their 
UV-Vis spectra were recorded. The Pc 4 GoMe suspension with the volume of 
200 µL in 1.5 mL eppendorf tube was irradiated with an 808 nm laser for 10 min 
(Scorpius D-700 laser, 2.83 W/cm2). The temperature of the suspension was 
monitored simultaneously with a FLIR i7 thermal imaging camera and recorded 
every 30 sec. The cool period followed by irradiation was recorded up to 20 mins 
or until it completely decreased to r.t.  
In vitro release of Pc 4 from Pc 4 GoMe 
To test the responsiveness of Pc 4 GoMe to intracellular high reducing 
environment, PBS plus 10 mM GSH were employed. Due to the solubility 
limitation of Pc 4, 1% tween was added to above solutions. Two hundred 
microliter of Pc 4 GoMe (at 1 mg/mL MSN) was loaded to 1.5 mL eppendorf tube 




samples were centrifugal at 16000 rcf for 10 mins and all the supernatant was 
transferred out and 1 mL of fresh media was supplemented in.  
To stimulate the laser trigger of Pc 4 GoMe, Pc 4 GoMe suspension was 
photoirradiated by NIR 808 nm laser for 10 mins after 24 h suspension in serum 
containing PBS buffer at 37 °C. The release of Pc 4 GoMe was continued to be 
monitored for another 24 h. At pre-determined time point, GoMe was centrifuged 
and all the supernatant was collected. The concentration of Pc 4 was determined 
by fluorescent plate reader, using the same release buffer as diluting buffer when 
preparing standard curves for Pc 4. 
Stability testing of Pc 4 GoMe 
Nanoparticles at the final concentration of MSN at 100 µg/mL were 
suspended in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine 
serum (FBS) at 37 °C. The size of nanoparticles was measured with DLS. To 
further investigate the integrity of GoMe during the circulation in physiological 
environment, the release behaviors of Pc 4 GoMe was tested in two release 
media. GoMe were incubated with PBS containing 10% or 50% of FBS at 37 °C 
via rotation (Thermoscientific tube revolver, 10 rpm) for different time points 
varies from 1 h to 48 h. At each time points, the released Pc 4 were collected 
through centrifugation and determined by a fluorescent plate reader. 
Quantification of cellular uptake of GoMe 
Cellular uptake of Pc 4 GoMe or MBA Pc 4 GoMe was quantified by flow 
cytometry and confocal microscopy. Cells were seeded in 12 well plates at 




the concentration of 1 µM for 0.5 h, 1 h or 2 h. Cells were incubated at 4 °C or 37 
°C, respectively. At each time point, cells were washed 3 times with cold PBS to 
remove un-bounded Pc 4 or Pc 4 GoMe. Cells were collected and fixed in 4% 
formaldehyde, and examined by FACS.   
To further investigate the role of MBA in facilitating the uptake of 
nanoparticles, the competition assay was carried out and the results were 
obtained with confocal microscopy. UMSCC 22A cells were pre-incubated with 
MBA (0.1 mg/mL) for 1 h. Different treatment groups were then added into each 
petri dish and reached the final Pc 4 concentration of 1 µM. After the co-
incubation of 3 h, cells were washed for 3 times and images were taken with 
Zeiss 710 LM at Pc 4, DAPI and DIC channels. 
Subcellular trafficking of Pc 4 GoMe 
Subcellular localization of NPs affects the efficacy of a photosensitizer, 
especially when mitochondria are the critical targets of Pc 4-PDT. Here we used 
confocal microscopy to investigate the subcellular location of Pc 4 in UMSCC 
22A cells. Cells were seeded in 10 mm petri dishes at 200,000 cells per dish, and 
were allowed to grow overnight. Cells were treated with Pc 4, Pc 4 GoMe or MBA 
Pc 4 GoMe at the Pc 4 concentration of 500 nM and incubated for 3 h. Cells were 
washed with PBS for three times and incubated with Mitotracker red FM (100 
nM) for 30 mins. Cells were then washed with PBS twice and incubated with 






Singlet oxygen detection in vitro 
In order to investigate the singlet oxygen level upon laser irradiation, two 
fluorescent dyes N,N-dimethylacrylamide (DMA) and singlet oxygen sensor 
green (SOSG) were employed. Briefly, Pc 4 or Pc 4 GoMe at the concentration of 
112 nM was dispersed in PBS or PBS supplemented with 10 nm GSH, 
respectively. To create a sink condition, the above media were supplemented 
with 0.5% tween 80. Stock solution of DMA was prepared in DMF at 
concentration of the 250 µM. Three milliliter Pc 4 or Pc 4 GoMe was mixed with 
DMA at the final concentration of 16.7 µM and kept stirring at r.t. The mixture was 
kept in vial with a cap opened and was irradiated with a 660 nm laser 
continuously for 10 mins. Two hundred microliter was sampled out every minute. 
The fluorescent intensity decay of DMA was analyzed (ex: 375 nm, em: 435 nm). 
Fluorescent intensity at 0 mins was defined as the mixture of Pc 4 with DMA 
without NIR irradiation. 
Fluorescent dye singlet oxygen sensor green (SOSG, Thermofisher 
scientific) were also applied to determine the singlet oxygen level. Briefly, Pc 4 or 
Pc 4 GoMe at the Pc 4 concentration of 1 µM was suspended in PBS containing 
1% tween 80. One hundred microliter suspension was added to a black 96 well 
plate (Costar), followed by the addition of 20 µl SOSG solution (stock solution 
prepared in methanol and diluted with HBSS buffer with a final concentration at 
50 µM). Each plate was irradiated with a 660 nm laser (18 mW/cm2) for 2, 6, 8 or 
10 mins and the control group was employed with the same amount of 




determined by measuring the fluorescent intensity at 525 nm upon the excitation 
at 504 nm. The full spectrum was recorded from 500 nm to 600 nm when excited 
at 490 nm with cutting off at 515 nm. SOSG assay was further employed to 
examine the Pc 4 responsiveness to GSH triggering. Pc 4 GoMe was incubated 
with 10 mM GSH for 3 h prior to NIR irradiation, and the fluorescent intensity at 
525 nm and full spectrum were recorded as described above. All experiments 
were carried out in triplicate.  
SOSG assay was also employed to investigate the intracellular singlet 
oxygen production. UMSCC 22A cells were seed in 12 well plate. When cell 
reach nearly confluence, Pc 4 GoMe, MBA Pc 4 GoMe or Pc 4 at the Pc 4 
concentration of 1 µM was added to each well and allowed to incubated for 16 h. 
Cells was then washed with PBS twice and incubated with SOSG solution for 2 h 
(HBSS solution at concentration of 1 µM). Cells were irradiated for 10 mins (660 
nm, 18 mW/cm2), followed by imaging with fluorescent microscope with the GFP 
channel and DIC channel. 
Measurement of mitochondrial membrane potential 
Changes of ΔΨm were monitored with JC-1 dye. Cells were seeded in 96 
well with a black 96 well plate and allowed to reach the confluence of 80% before 
the experiment. Cells were co-incubated with Pc 4, Pc 4 GoMe at the Pc 4 
concentration of 200 nM or 1 µM for 16 h. Media was then replaced and cells 
were irradiated with a 660nm laser at 200 mJ/cm2. After 5 h incubation, cells 
were stained with JC-1 dye diluted media (10 µg/mL) for 30 mins. Afterwards, 




excitation of 485 nm and the emission of 525 nm as well as the excitation at 535 
nm and emission of 590 nm was recorded. Control plate was prepared in the 
same method except without receiving laser irradiation. 
Cell viability upon PDT and PTT treatment 
To visualize the direct cytotoxicity effect of PTT or the combination of PDT 
and PTT on cancer cells, a live/dead staining kit was employed. UMSCC 22A 
were seeded in a 24 well plate at the density of 200,000 cell per well and allowed 
for overnight incubation. Cells were treated with Pc 4, Pc 4 GoMe or MBA Pc 4 
GoMe containing media (at the Pc 4 concentration of at 100 nM) for 3 h. After the 
treatment, the old media were replaced by fresh media. Subsequently, cells 
received different photoirradiation treatments including: 1) 660 nm PDT at 200 
mJ/cm2, 2) 808 nm PTT for 10 mins, 3) firstly irradiated with PDT followed by 
PTT. Media were removed and cells were stained with live/dead staining kit in 
PBS for 30 mins according to manufacturer’s instruction. Images were taken 
immediately with a fluorescent microscope with FITC, Texas red and DIC 
channels. 
Cell viability after receiving PDT and PTT treatment was quantitatively 
evaluated by MTT assay. UMSCC 22A and A2058 cells were seeded at density 
of 20,000 per well in 96 well plates with either transparent or black wells and 
incubated at 37 °C under 5% CO2 overnight. Pc 4, Pc 4 GoMe or MBA Pc 4 
GoMe at various concentration were incubated with cells in dark for 3 h. After 
twice washing with PBS, cells received photoirradiation accordingly. For PDT 




irradiated under the laser (λ=660 nm, 200 mJ/cm2). For PTT treatment groups, 
cells were seeded in clear 96 well plates and irradiated under the laser (λ=808 
nm, t=10 mins). For the combination therapy of PDT and PTT, cells were either 
first receiving PDT followed immediately with PTT, or first receiving PTT followed 
by PDT. After the photoirradiation, cells were further incubated in dark for 48 h. 
Afterwards, the old media were replaced with 100 µL fresh media containing 1 
mg/mL MTT reagent and continued to incubate for 4 h. The formed MTT crystal 
was dissolved with a stop solution and the finally optical density of the medium 
was measured using a microplate reader (ELX808, Bio-Tech Instrument, Inc) at λ 
= 595 nm. 
Combination therapy in vivo 
All animal experiments were conducted in accordance with NIH 
regulations and approved by the Institutional Animal Care and Use Committee of 
the University of South Carolina. Female athymic mice at 6 to 8 weeks (nu/nu) 
were obtained from Jackson laboratory. UMSCC 22A cells were injected 
subcutaneously into both flanks of mice (2 million cells per implant). The tumor 
volume was measured by a digital capillary and calculated according to the 
following formula: Tumor volume = (tumor length) × (tumor width) 2/2. When the 
tumor reached to 50 mm3, mice were divided into 6 groups: (1) saline; (2) Pc 4 
with PDT laser at the dose of 50 J/cm2, (3) Pc 4 GoMe was injected into tumor. 
After the injection of 1 h, mice were treated with PDT at the dose of 50 J/cm2 for 
the duration of 25 mins. (4) Pc 4 GoMe were injected into tumor. After the 




the mice were then anesthetized and received PTT for 2 mins (808 nm, 2.8 
W/cm2). (5) MBA Pc 4 GoMe was injected into tumor. After the injection of 1 h, 
mice were treated with PDT at the dose of 50 J/cm2 (6) MBA Pc 4 GoMe was 
injected into tumor. After the injection of 1 h, mice were treated with PDT at the 
dose of 50 J/cm2. Immediately, the mice were anesthetized and received PTT for 
2 mins (808 nm, 2.8 W/cm2). Pc 4 dose was kept at 0.5 mg/kg mice. At the end of 
28 days, mice were sacrificed and tumors were harvested and weighed. The 
isolated tumors were fixed in 10% neutralized formalin solution and changed to a 
gradient of sucrose solutions until they sink down in the sucrose solution before 
embedding with OCT. Tumor was sliced into 10 µm thickness and followed with 
standard H&E staining protocol. The inhibition effect of tumor growth was 
calculated based on the following equation: inhibition effect I (%) = (tumors 
weight in the groups of saline - tumors weight in the treatment group)/ tumors 
weight in the groups of saline × 100%. 
Acute cytotoxicity of Pc 4 GoMe was evaluated in UMSCC 22A bearing 
mice. After injection of the dose of Pc 4 GoMe or MBA Pc 4 GoMe, mice were 
sacrificed in the next 24 hours. All the organs were collected and evaluated 



















































Figure 3.1 The scheme for the combination therapy of PDT and PTT using MBA 









Figure 3.2 Physical characterization of MBA Pc 4 GoMe. Transmission electron 
microscope images of Pc 4-MSN (A), Pc 4 GoMe (B), MBA Pc 4 GoMe (C), 
Scanning electron microscope image of PC 4 GoMe (D). (E) 1H-NMR of Mal-
PEG-MBA in CDCl3. (F) The UV-Spectra of Pc 4, Pc 4-MSN, PC 4 GoMe and 






Figure 3.3 Hydrodynamic size and surface charge of Pc 4 GoMe and its 
photothermal response. (A) Hydrodynamic size of MBA Pc 4 GoMe was 
determined by dynamic light scattering, and surface charge was monitored by 
Malvern nano sizer. (B) UV-Vis spectra of PC 4 GoMe at different concentrations. 
(C) Photothermal response of Pc 4 GoMe at different concentrations coupled 
with the 808 nm laser. (D) A heating and cooling cycle of PC 4 GoMe at OD = 






Figure 3.4 Pc 4 GoMe release and colloid stability. (A) The Pc 4 release kinetics 
of Pc 4 GoMe. (B) The release of Pc 4 was in response to laser irradiation at 808 
nm. Arrow represents the time point when the laser was applied. (C) Stability of 
Pc 4 GoMe in serum containing media. (D) Hydrodynamic size changes of Pc 4 
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Figure 3.5 Determination of singlet oxygen generation upon NIR 660 nm 
irradiation. (A) DMA was used to determine the generation of singlet oxygen from 
Pc 4 GoMe after the co-incubation with GSH 10 mM. (B) The fluorescence 
intensity change of SOSG was used to determine the release of Pc 4 from Pc 4 
GoMe after the co-incubation with GSH 10 mM. (C) The spectra of SOSG in 
solution with Pc 4 with photoirradiation over time. (D) The spectra of SOSG in 
solution with Pc 4 GoMe with photoirradiation over time. (E) The spectra of 
SOSG in solution with Pc 4 GoMe supplemented with 10 mM GSH after 
photoirradiation over time. Both Pc 4 and Pc 4 GoMe solution mixed with SOSG 
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Figure 3.6 SOSG singlet oxygen detection in UMSCC 22A cells treating with Pc 
4, Pc 4 GoMe and MBA-Pc 4 GoMe with or without a 660 nm laser irradiation 







Figure 3.7 The uptake of nanoparticles in UMSCC 22A cells. FACS of UMSCC 
22A cells treated with free Pc 4, Pc 4 GoMe and MBA Pc 4 GoMe at 37 °C for 
0.5  h (A), 1 h (B), and 2 h (C). FACS of UMSCC 22A cells treated with free Pc 4, 
Pc 4 GoMe and MBA Pc 4 GoMe at 4 °C for 0.5 h (D), 1 h (E), and 2 h (F). (G) 
Confocal microscopy images of Pc 4, Pc 4 GoMe or MBA-Pc 4 GoMe in UMSCC 








































































Figure 3.8 Pc 4 GoMe localized in the mitochondria and caused its membrane 
potential change. (A) Confocal microscope images of UMSCC 22A incubated 
with Pc 4, Pc 4 GoMe and MBA Pc 4 GoMe at 1 µM and stained with Hoechst 
33342 (blue), Mito tracker FM (yellow), Pc 4 (red). (B) JC-1 staining of UMSCC 
22A cells treated with Pc 4, Pc 4 GoMe followed by PDT (200 mJ/cm2). (C) JC-1 
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Figure 3.9 Cytotoxic effect of MBA Pc 4 GoMe coupled with PDT and PTT. (A-H) 
Live/dead staining of UMSCC 22A cells after photoirradiation of PDT (200 
mJ/cm2) or PDT+PTT (2.8 W/cm2, 10 mins). Cytotoxicity of different treatments 
coupled with PDT in UMSCC 22A (I) and A 2058 (K). Cytotoxicity of different 
treatments coupled with PTT and PDT with different sequences in UMSCC 22A 
(J) and in A 2058 with the sequence of first apply PTT and then PDT (L).
UMSCC 22 A + PDT
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Figure 3.10 Combination therapy of PTT and PDT for UMSCC 22A head and 
neck cancer in vivo. (A) Bodyweight change curves. (B) Tumor volumes change 
curves. (C) Average weight of tumors in all treatments. (D) Photographs of 
control mice (left mice), Pc 4 GoMe with dual laser (middle mice), MBA Pc 4 








Figure 3.11 Histology analysis of liver and tumor of mice. (A) H&E staining of 
tumor section of the mice treated with saline, Pc4 + PDT, Pc 4 GoMe + PDT, Pc 
4 GoMe + dual laser, MBA Pc 4 GoMe + PDT, MBA Pc 4 GoMe + dual Laser. (B) 





Glycol chitosan mediated co-delivery of suramin and doxorubicin for the 
treatment of breast cancer metastasis 
ABSTRACT 
Suramin (SM), an anti-angiogenesis agent, has been evaluated in various 
clinical trials for cancer therapy. However, it was eventually withdrawn due to its 
narrow therapeutic window and the side effects associated with multiple targets. 
In this work, we developed a simple but effective system by using a non-toxic 
dose of suramin together with a chemotherapeutic agents for the treatment of 
metastatic triple negative breast cancer. Suramin and doxorubicin (DOX) were 
encapsulated into nanoparticles by gentle gelation with glycol chitosan (GCS) 
through one step preparation. The formed nanoparticles were small size and 
uniform range, exhibiting a surprisingly high loading capacity of suramin. In vitro 
experiments proved the effectiveness of nanoparticles in inhibiting cell migration 
and invasion. The intravenous (i.v) injection of nanoparticles significantly extends 
the survive rate of animals with breast cancer lung metastasis and greatly 
reduces the cardiotoxicity compared to the combination of free drugs.  
INTRODUCTION 
Breast cancer is the most common cancer in women worldwide, while 
metastasis is the major cause of human cancer death.85 Metastasis is a complex 




extravasation in circulation system, and angiogenesis and growth in the distant 
location.86 Perhaps the most effective way of treating metastatic cancer is to kill 
cancer cells before the dissemination from primary foci. However, the clinical 
deficiency in accurately detecting small tumor mass is a limiting factor for curable 
cancer treatment. When a breast cancer patient is diagnosed with distant 
metastasis, the five-year relative survival rate drops from 98.6% to 23.4%.87 
Currently, various treatments are available for patients with different stages of 
metastasis. There is barely any FDA approved treatment other than prophylactic 
and vaccination before the diagnosis of circulating tumor cells (CTC). Once a 
patient is diagnosed with CTC, or even micro-metastasis, surgery or radiation 
plus systemic therapy will be applied. For high risk patients, metronomic 
chemotherapy and anti-angiogenesis might be necessary.86  
Angiogenesis, a hallmark of malignant disease, is a process to form new 
blood vessels based on the original ones, which is critical for tumor progression. 
CTCs up-regulate several pro-angiogenic factors, such as vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF), to adapt to the 
new tumor microenvironments.88 The combination of bevacizumab, an inhibitor of 
VEGF, with paclitaxel/carboplatin significantly increased the median survival 
month of patients diagnosed with metastatic colorectal cancer or advanced 
NSCLC in a phase III trial.89 However, for patients with the late stage of breast 





One of the major targets for anti-angiogenesis is the FGF family. FGFs 
and their receptors play crucial roles in many fundamental processes from 
embryogenesis to adult life, such as proliferation, differentiation, migration, 
angiogenesis and wounding healing.91 Like many other mitogens, FGFs act like a 
double-edged sword and deregulation of the signaling causes various types of 
human cancer that arises in different tissues including lung, breast, ovarian and 
prostate.91a, 92 Therefore, FGF/FGFRs have been extensively studied as a 
potential target for cancer treatment. Many selective or non-selective 
pharmaceutical inhibitors for FGFs and FGFRs have been developed for cancer 
treatment.93  
Suramin, a polysulfonated naphthylurea that inhibits VEGF and bFGF, is 
reported as an anti-angiogenesis agent.94 Suramin reversed the FGF induced 
drug resistance at the concentration of 1-17 µM in human prostate PC3 cells in 
the presence of doxorubicin (DOX).94f The combination of suramin and various 
chemotherapeutic agents have proven effective in various mice models and 
entered clinical trials. The combination of suramin and paclitaxel inhibited the 
brain metastatic cancer by injecting suramin at 10 mg/kg and PTX at 10 
mg/ml.94h The nontoxic dose of suramin with DOX were suggested for the 
treatment of prostate cancer.94f, 95 The co-delivery of suramin enhanced the 
activity of DOX in dogs with spontaneous cancers.96 In the xenograft prostate 
mouse model, the addition of suramin to DOX inhibited tumor growth by 60%.94f 
Although suramin has a direct effect on cancer cells, high dose of suramin not 




showed that chemical conjugates of low molecular weight heparin and suramin 
which had a higher affinity to the heparin binding domain of VEGF165, which 
significantly inhibited the tumor progression in a SCC-7 tumor bearing mouse 
model.94c However, this mouse model was a xenograft primary tumor model.  
In this study, a simple yet effective nanoparticle system is carried out for 
breast cancer lung metastasis therapy. Suramin and glycol chitosan (GCS) forms 
the nanoparticle system by electrostatistic effect, and DOX is encapsulated 
inside. Both suramin and GCS showed inhibitory effect on the migration and 
invasion of MDA-MB-231 breast cancer cell migration. Suramin at a non-toxic 
dose was able to enhance the anticancer efficacy of DOX both in vitro and in 
vivo. In addition, all of the components in this system are highly biocompatible, 
easy for large scale fabrication, which make this system very translatable for the 
metastatic breast cancer treatment.  
RESULTS  
DOX encapsulated glycol chitosan/suramin (GCS-SM/DOX) NP synthesis 
It has been reported that chitosan can form hydrogels with 
tripolyphosphate (TPP)98 and alginate.99 Many factors can affect the size of 
nanoparticles, especially the TPP to chitosan ratio, pH of the buffer and the ionic 
strength of the dissolution medium.98b, 100 As anionic and cationic compounds 
account for the majority weight of the delivery system, the loading capacity of 
therapeutic agents will be greatly reduced if they are not an active 
pharmaceutical ingredient. Moreover, a few reports showed that chitosan was 




of creating GCS-SM NPs through the gelation process between the sulfate 
groups on suramin and amine groups on glycol chitosan, where suramin acted as 
an anionic compartment and glycol chitosan acted as a cationic compartment 
(Figure 4.1). The relationships among particle size, suramin content in the final 
formulation, pH of the buffer, as well as the concentration of suramin were shown 
in Figure 4.2A-D. In order to examine the effect of suramin concentration on the 
nanoparticle size, we fixed the glycol chitosan concentration at 2.5 mg/mL in PBS 
buffer. With the suramin concentration varying from 25% to 5% (weight ratio to 
glycol chitosan), the hydrodynamic size of nanoparticle was increased from 220 
nm to 277 nm along with the increased PDI (polydispersity index). Next step, we 
varied the pH of the buffer from 6 to 7.4. The size of nanoparticles was 
maintained at 210 nm level at pH 6. The particle size increased to 298 nm when 
the buffer pH was adjusted to 7.4. Furthermore, we found that too low or too high 
pH inhibited the formation of nanoparticles. In addition, within the range of 0.1 to 
0.5 mg/mL, the concentration of SM did not have significant effect on 
nanoparticle size. However, when the concentration of SM reached 1 mg/ mL, 
nanoparticle had a final size over 600 nm with a PDI of 0.25 (Figure 4.2C). The 
loading of DOX had no significantly impact on final hydrodynamic size of the 
nanoparticle. With DOX loading content from 1% to 10% of chitosan, the size of 
nanoparticles only slightly shifted from 186 nm to 219 nm (Figure 4.2D).  
Characterization of GCS-SM/DOX NP  
With the above optimized condition, we synthesized nanoparticle with SM 




0.5 mg/mL SM. The final hydrodynamic size of nanoparticle was 186 nm, with a 
slightly positive surface charge as shown in Figure 4.3A. Transmission electron 
microscopy revealed that these nanoparticles were spherical with the average 
size of 49.09±11.52 nm (Figure 4.3B). We reasoned that the highly swelling and 
hydrated glycol chitosan caused the dramatically increased size of nanoparticles 
in aqueous solution. 
Figure 4.3C showed the release behaviors of suramin and DOX from the 
nanoparticles. It was revealed that DOX and suramin shared a similar release 
pattern, in which after 8 h of incubation in PBS 7.4, both the DOX and suramin 
had reached the platform at around 80%. The simultaneously release pattern for 
DOX and suramin ascertained the optimized ratio between two drugs to maintain 
the same from the point of the preparation to the in vivo release process. Since 
the complex was slightly positive, there is a concern about the colloid stability of 
nanoparticles. The stability of nanoparticles was evaluated through the long-term 
incubation of NPs in PBS and short term incubation of NPs supplemented with 
FBS. Figure 4.3D showed that these NPs were stable and did not aggregate in 
10% serum containing media. NPs were very stable in PBS environment as 
evidenced by no size increase after two weeks incubation at 37ºC (Figure 4.3E). 
GCS-SM/DOX NP inhibits cell migration and invasion 
To investigate the effect of suramin or suramin nanoparticles on breast 
cancer cell migration, wound healing assay and transwell invasion assay were 
carried out. In the wound healing assay, effects of different treatments on cell 




The average speed for cell migration was measured by the wound 
distance divided by the time consumed to completely heal. Figure 4.4 A and B 
showed that suramin significantly inhibited cell migration and the effect was 
enhanced by GCS-SM nanoparticle (Control group had an average speed of 
28.17 µm/h, which was twice as fast as the group treated with suramin (Figure 
4.4C). Interestingly, glycol chitosan also showed an obviously inhibiting effect on 
cell migration with an average speed of 18.17 µm/h. A study showed that 100 
µg/mL glycated chitosan significantly inhibited the migration of 4T1 and MDA-
MB-231 cells, and reasoned the cause of the inhibition was that glycated 
chitosan up-regulated E-cadherin and down-regulated slug and twist 1.102 Based 
on the structural similarity, we postulate that GCS has a similar (if not the same) 
function as glycated chitosan. Next, we tested whether the effect of suramin and 
suramin nanoparticle on cell migration was due to its cytotoxic effect. We found 
that neither suramin nor GCS-SM NP inhibited cell proliferation at the 
concentration up to 200 µM after 24 h treatment (Figure 4.4D), which indicates 
that the inhibition of cell migration is not towing to the cytotoxic effect. 
To investigate the inhibition effect of SM and GCS-SM NPs on cell 
invasion, we performed a transwell invasion assay. Figure 4.5 showed that the 
invaded cell number per view area was significantly decreased from 951.75 in 
the control group to 718 in the group treated with 40 µM SM. GCS-SM NPs 
further decreased the number to 483. Thus, we proved that SM or GCS-SM NPs 





Cellular uptake of GCS-SM/DOX NPs 
To measure GCS-SM/DOX NPs uptake efficiency in vitro, we treated 
MDA-MB-231 cells with free drugs, free-drug combinations, and GCS-SM/DOX 
NPs. After 1, 3, and 6 h of incubation, cells were analyzed by the flow cytometry 
(FACS) and confocal microscopy. Figure 4.6A showed that free DOX entered 
cells much slower than GCS-SM/DOX NPs: after 1h of treatment, NPs treatment 
exhibited a much stronger red fluorescence signal inside cell than free DOX; after 
3h, almost all of DOX that delivered by NPs was in nuclei while a lot of DOX from 
free DOX treatment still stayed in cytosol. We next compared the cellular uptake 
behaviors of free DOX or GCS-SM/DOX NPs at 3 h and 6 h in presence or 
absence of a/b FGF using FACS (Figure 4.6B). In presence of a/b FGF, GCS-
SM/DOX NPs treatment showed a much better DOX uptake compared to free 
DOX. Without a/b FGF treatment, no significant difference in uptake was 
observed between free DOX and GCS-SM/DOX NPs treatments at 3 h and 6 h. 
It’s an interesting phenomenon that a/b FGF causes the differences in DOX 
uptake between GCS-SM/DOX NPs and free DOX, we reason that FGF might 
induced chemo-resistance103 while suramin could sensitizer those drug resistant 
cells.  
Suramin and DOX have synergistic growth inhibitory effect of MDA-MB-231 
cells  
Suramin showed biphasic effects on the proliferation of cancer cells.104 On 
one hand, as a non-specific growth factor inhibitor, it inhibits angiogenesis of the 




directly. Although it has been reported that suramin kills cancer cells in a dose- 
and time-dependent manner,94d, 94g, 105 the cell killing mechanism is still not fully 
understood.  
Since SM was reported to induce the drug cross resistance against 
doxorubicin and amsacrine at high concentration,106 it is crucial to find out the 
ratio that keeps the combination of DOX and suramin achieving synergistic effect 
while not inducing side effects. After 24 h treatment of 200 µM SM in form of 
either free SM or SM NPs, no cytotoxicity was observed. However, after 48 h of 
treatment, the IC50 of SM and SM NPs was 200 µM and 62.97 µM, respectively 
(Figure 4.7B). In this study we decided to test SM at nontoxic dose (10 µM, 20 
µM and 100 µM) when combined with doxorubicin. We first investigated whether 
free-drug combinations at a non-toxic dose of suramin increased DOX 
cytotoxicity in presence of a/b FGF or not. Figure 4.7A showed that the 
cytotoxicity of DOX was greatly enhanced by the addition of 10 µM SM, but 
further increase of SM concentration (20 µM or 100 µM) did not further enhance 
its cytotoxicity (Figure 4.7A)  
SM was reported to enter human micro vascular endothelial cells through 
an active process involving caveolae system,107 where the zwitterionic 
nanoparticle may enter cell membrane through membrane penetration.108 We 
reasoned that the synergistic effect was caused by the delivery of SM. To 
optimize the synergistic effect, different ratios of GCS-SM NPs to DOX were 
tested in MDA-MB-231 cells. The results in Figure 4.7C showed that synergistic 




(Additive effect with CI = 1, synergism with CI < 1, and antagonism with CI > 1).49 
We further created a profile of synergistic growth inhibition of MDA-MB-231 cells 
under different concentrations of SM at 3 GCS-SM/DOX ratios (Figure 4.7D).  
GCS-SM/DOX NP inhibits proliferation and metastasis of cancer cells in a 
tumor-bearing mouse model 
Based on the in vitro results, we further tested the anti-metastatic efficacy 
of GSC-SM/DOX NP in a breast cancer lung metastasis model in nude mice. 
There are two mostly used methods to generate breast cancer lung metastasis 
animal models, either by orthotropic implantation of cancer cells in the mammary 
gland or tail vein injection of cancer cells. We applied the tail vein injection not 
only because it was faster but also produced tumors mainly in lung tissue with 
the similar genetic profiles.109 It was previously reported that if the treatment was 
started on the first day of the cell implantation, the number of metastasis would 
be greatly inhibited by the combination of chemotherapy and suramin.94h To allow 
cancer cells to adapt to the new environment, we started the treatment on the 
second day after cancer cell inoculation. The effect of combination treatment on 
the breast cancer lung metastasis was evaluated by bioluminescence for ventral 
images. Figure 4.8B showed that the high sensitivity of luminescence imaging 
system and that the signal was highly correlated with cell number in the range of 
125 and 8000 cells/well. 
The whole body photoemission rate was measured to indicate the cell 
proliferation and the progression of metastasis over the next 6 weeks (Figure 




accumulated at the stem of tail for 4 weeks and the signal for lung metastasis 
was dramatically increased after week 5. For the free SM or SM-NPs treatment, 
both the proliferation of cancer cells and metastasis were slowed down 
compared to the control. For the free drug combination treatment, the 
proliferation of cancer cells was dramatically inhibited and no detectable lung 
metastasis was observed during the experimental period, while SM/DOX NPs 
completely eradicated the cancer cells from it treated mice. Furthermore, the 
injection of free SM, free DOX/suramin, SM NPs and GCS-SM/DOX NPs did not 
cause significant weight loss (Figure 4.8C).  
Kaplan-Meier survival analysis was carried out for 12 weeks (Figure 
4.9A). The saline treated group showed a 100% lethal by 68 days. SM and SM 
NPs treatments had moderately increased survival rates. The median survival 
time for control mice was 64.5 days while for SM treatment alone reached 76.5 
days. For the free combination group and GCS-SM/DOX nanoparticle group, the 
median survival time was significantly improved (P=0.0038 and 0.021 
respectively). The median survival time was extended to 81.5 days for free drug 
combination treatment group, and for GCS-SM/DOX nanoparticle treatment 
group the time was extended to higher than 85 days. After weeks 12, the free 
drug combination group has the survival rate of 50% while GCS-SM/DOX NPs 
group achieved 60%. As the metastatic site formed a colony instead of the 
formation of discrete tumors using the method of tail vein injection,110 we further 
evaluated the metastatic status of each group by measuring the lung weight 




lung weight compared to the control, while the free drug combination and the 
nanoparticle combination treatments reduced lung weight by 53% (P=0.0218) 
and 56% (P=0.0089), respectively.  
At the end of experiment, an ex vivo organ images were obtained by 
injecting luciferin i.v. to mice before they were sacrificed (Figure 4.10). Images of 
the control group were taken separately due to the fact that no mice was survived 
at the end of the whole experiment, but the same imaging protocol was carried 
out throughout all groups. Compared to control group, other mice that were 
survived till the end of the experiment showed no significantly visible 
luminescence, indicating that the metastasis was highly inhibited in these mice 
(Figure 4.10A and B). As injected MDA-MB-231 cells were constitutively 
expressing both GFP and luciferase proteins, we were able to directly visualize 
the metastatic cancer cells in the lung in GFP channel. It was found out that the 
GFP expression was positively correlated with the luminescent signal shown 
above, and GCS-SM/DOX NP treated mice showed the least GFP signal in the 
lung (Figure 4.10C). 
Evaluation of GCS-SM/DOX NP treatment by pathology analysis  
DOX is an effective anticancer drug with notorious cardiotoxic effects.111 It 
is suggested that the cardiotoxic effects primarily come from iron accumulation in 
mitochondria and the production of ROS. The DOX-dependent cardiac damage 
often results in irregular-aligned mitochondria and reduced perivascular fibrosis 
and detectable by transmission electron microscopy (TEM) images.111-112 




combination treated group exhibited misaligned mitochondria (Figure 4.9C), 
indicating the result of cardiotoxicity. However, no abnormal mitochondria 
alignment was detected in the co-delivery of suramin and DOX by 
nanoformulation. 
Histologic analysis of lung and liver from each treatment was shown in 
Figure 4.11. Based on the boundary between the normal and tumor tissue, we 
found that the lung in control group was almost fully covered by cancer cells, and 
that both free SM and SM NPs treated groups have a mild reduction in the 
occupied area ratio between tumor and normal tissue size. In the free drug 
combination and the GCS-SM/DOX NP groups, no visible tumor was found in 
their tissue sections. There was no significant difference in histology among the 
livers from all groups. 
CONLCUSION 
In summary, we have successfully designed an efficient tool for co-loading 
anti-metastasis drug suramin and chemotherapeutic drug DOX with high loading 
content. At non-toxic dose of suramin, GCS-SM NPs were able to reduce the 
migration speed as well as invaded cells by half. In vivo experiment showed 
GCS-SM/DOX nanoparticle can greatly inhibit breast cancer lung metastases 
and improve the survival time for mice without causing cardiotoxicity. 
MATERIALS AND METHODS 
Materials 
Glycol chitosan, suramin sodium salt, doxorubicin hydrochloride and eosin 
Y were purchased from Sigma. Acidic fibroblast growth factor (aFGF) and basic 




prep was obtained from Sigma. Bradford protein assay kit was purchased from 
Bio-Rad. Luciferin was obtained from Merck Millipore. Gill’s Hematoxylin No.2 
was purchased from VWR.  
Preparation of GCS-SM NPs 
GCS-SM NPs were prepared by the mild ionic gelation technique between 
the sulfate groups in suramin and amine group in glycol chitosan. Different 
suramin concentration or amount, gelation solution pH, and doxorubicin were 
investigated, respectively. Typically, glycol chitosan was dissolved in PBS pH 7.0 
buffer with an ionic strength at 20 mM to achieve the concentration of 2.4 mg/mL. 
Suramin was dissolved in the same buffer at the concentration of 0.5 mg/mL. 
Doxorubicin hydrochloride was dissolved in ddH2O at 1 mg/mL. One and a half 
milliliter of suramin solution prepared above was mixing with doxorubicin solution 
first, and then injected slowly to 2.5 mL glycol chitosan solution at 0.2 mL/min 
with a microinjection pump (Harvard apparatus) under stirring (400 rpm) at room 
temperature. The mixture was stirred for 30 mins to allow the formation of 
nanoparticles. Afterwards, the mixture was centrifuged at 3000 rpm for 5 mins 
and large aggregates were removed. Nanoparticles were lyophilized with 1% 
trehalose (w/w) and stored at 4ºC prior to use. 
The size and surface charge (ξ-potential) of the complexes were 
measured using a Zetasizer Nano-ZS (Malvern, UK) at pH 7.4. The morphology 
of the GCS-SM NPs was observed by transmission electron microscopy (Hitachi 
H-800 TEM) using a formvar/carbon coated Copper Grids (Electron Microscopy 




ddH2O (3 ×) to remove the remaining salt, and dried with a tissue paper. 
Doxorubicin concentration and suramin concentration were determined by UV-
Vis spectrometer (Beckman, DU650) at 480 nm and 312 nm respectively. 
Release kinetics and colloid stability of GCS-SM NPs 
Two milliliter of GCS-SM NPs were loaded in the dialysis bags (MWCO: 6-
8 KDa, Spectrum laboratories) and were put into 25 mL of pH 7.4,100 mM PBS 
at 37 °C under continually stirring. At predesigned time, 1 mL sample was taken 
and supplemented with 1 mL corresponding fresh medium. Samples were 
determined by UV-Vis spectrometer. All experiments were carried out in triplicate 
independently. 
Nanoparticles were suspended in PBS 7.4 supplemented with different 
amounts of fetal bovine serum (FBS), ranging from 10% to 50% of FBS, at the 
final concentration of suramin at 100 µM at 37 °C. Nanoparticles size was 
measured at pre-determined time points with DLS. 
Quantification of cellular uptake of GCS-SM NPs 
Cellular uptake of GCS-SM NPs was quantified by flow cytometry and 
confocal microscopy. MDA-MB-231 cells were seeded in 12 well plates at 
200,000 cells per well and treated with doxorubicin or GCS-SM/DOX NPs at the 
DOX concentration of 1 µM for 3 h. Afterwards, cells were washed 3 times with 
cold PBS to remove un-bounded doxorubicin or nanoparticles. Cells were 
collected and fixed in 4% formaldehyde, and examined by FACS. 
To further investigate the uptake behaviors of nanoparticles, confocal 




were seeded in the petri dishes and different treatment groups were then added 
into each petri dish at the Dox concentration of 1 µg/mL. After 3 h co-incubation, 
cells were washed for 3 times and images were taken with Zeiss 710 LM. 
Wound healing assay 
The migration of breast cancer cell was evaluated with a wound healing 
assay. Living videos of cell migration in a 24 well plate were obtained with Zeiss 
confocal microscopy. Cells were pretreatment with a/b FGF and the wound was 
created by scraping the cell monolayer in a straight line with a p200 tip, and cell 
debris were removed by three time washing with PBS. Cells were incubated with 
different treatments and were allowed to grow in 37ºC chamber with 5% CO2 
condition for 24 h.  
Transwell invasion assay 
Cells were seeded with BD cell culture insert with the pore size of 8 µm 
(BD, Biosciences). The inserts were pre-coated with Matrigel at 0.2 mg/mL for 50 
µL (dilution from BD Matrigel stock 10 mg/mL with coating buffer). Cells were 
seeded at 200,000 per 50 µL in the inserts in FBS free DMEM media. Suramin or 
GCS-SM NPs was then added to the inserts in 50 µL serum free medium. Lower 
chamber was added with 2 mL 10% FBS DMEM containing different treatments. 
After 16 h, the inserts were washed with PBS, fixed in 4% formaldehyde, and 
permeablized with methanol. Subsequently, cells were stained with hematoxylin 
and washed twice with PBS. The membrane in the inserts were then cut and 
mounted on the coverslip, and the cell number was counted with a light 




and the invasion rate was expressed by the average number of cells per 
microscopic field. 
Cell viability assay 
The anticancer activities of the combination of DOX and suramin was first 
investigated with MTT assay. Two cell lines, MDA-MB-231 and MDA-MB-231 
pre-incubated with a/b FGF, were treated with DOX, suramin and the 
combination of DOX with Suramin at 10 to 50 µM. Cells were seeded in 96-well 
plates at an initial density of 20,000 cells/well in 150 mL of DMEM medium 
supplemented with 100 U penicillin/streptomycin and 10% FBS. After 24 h of 
incubation, the medium was replaced with 150 µL of fresh medium containing 
different treatments and incubated for another 48 h. Afterwards, the media were 
replaced with 100 µL fresh media containing 1 mg/mL MTT reagent and 
incubated for another 4 h. The formed MTT crystal was dissolved with a stop 
solution and the finally optical density of the medium was measured using a 
microplate reader (ELX808, Bio-Tech Instrument, Inc) at λ = 595 nm.  
In vivo experiment 
All animal experiments were conducted in accordance with NIH 
regulations and approved by the Institutional Animal Care and Use Committee of 
the University of South Carolina. Female athymic mice at 6 to 8 weeks (nu/nu) 
were obtained from Jackson laboratory. MDA-MB-231-Luc-GFP cells were 
implanted by tail vein injecting 100 µL cell suspension (2×106). Mice were then 
randomly divided into 5 groups: 1) mice were treated with saline only; 2) Mice 




treated with suramin and Doxorubicin at dose of 3.5 mg/kg of suramin and 0.5 
mg/kg of Doxorubicin once per week; 4) mice were treated with GCS-SM NPs at 
the dose of 3.5 mg/kg once per week; 5) mice were treated with GCS-SM/DOX 
NPs at the equivalent dose once per week. The whole treatment procedure 
lasted for two months and the progression of tumor cells were monitored the 
luminescence with IVIS Lumia system by i.v. injection of luciferin (30 mg/mL, 50 
µL) every week. Bodyweight of mice were measured every week. At the endpoint 
of each mouse, all the organs were isolated and lung weight was measured. 
Fluorescent images of lungs were also taken. Isolated organs were fixed in 10% 
neutralized formalin solution and embedded in paraffin. Tumor was sliced into 5 














Figure 4.2 (A) The effects of SM amount, (B) pH of the buffer, (C) SM 
concentration, (D) and the loading content of DOX on the hydrodynamic size and 






















Figure 4.3 Characterization of GCS-SM NP. (A) Hydrodynamic size measure by 
DLS and surface charge measured by Zeta sizer. (B) Transmission electron 
microscopy images of GCS-SM/DOX NPs with 20 K and 100 K magnification, 
respectively. (Left) 20 K magnification, (Right) 100 K magnification. Scale bar: 
200 nm and 50 nm. (C) In vitro release of suramin and doxorubicin in PBS. (D) 
Hydrodynamic size of GCS-SM NPs when co-incubated with 10%-30% FBS 







Figure 4.4 The effect of GCS-SM NP on the migration of MDA-MB-231 cells. (A) 
Photographs of cell migration after treated with SM, GCS or GCS-SM NP at 
different concentrations through a living cell imaging. Scale bar: 50 µm. (B) 
Quantification of migration distance of each time point. (C) Average migration 
speed of each treatment groups. (D) Cytotoxicity of SM or SM NPs toward MDA-







Figure 4.5 Cell invasion inhibitory effect. (A) Representative images of cells 
treated with SM or GCS-SM NPs at different concentrations. (B) Cell counting 






Figure 4.6 The uptake of nanoparticles in MDA-MB-231 cells. (A) Confocal 
microscopy images of MDA-MB-231 cells after treating with DOX or GCS-
SM/DOX NP for 3 h. Blue-Hoechst 33342, red-DOX. (B) FACS of MDA-MB-231 
cells treated with free DOX or GCS-SM/DOX NP for 3 h or 6 h. (Left: cells treated 






Figure 4.7 Synergistic effect of DOX and GCS-SM NPs in MDA-MB-231 cells. 
(A) Cell viability of DOX in combination with suramin at different concentration. 
(B) The cytotoxicity of Suramin and SM NP after 48 h treatment. (C) CI index 
calculation of DOX and GCS-SM NPs mixing at different ratio. (D) Cell viability of 










































































Figure 4.8 The inhibitory effect of GCS-SM/DOX NP on tumor growth in vivo 
using bioluminescence assay. (A) Luminescence images of mice in different 
treatments from week 1 to week 6. (B) Cell luminescence as a function of cell 







Figure 4.9 GCS-SM/DOX NP increased survival rate and reduced side effects. 
(A) Survive curves of different treatments, (B) lung weight in different treatments, 
(C) and the transmittance electron microscopy images of heart tissues from 
control, GCS-SM/DOX NP, and the free drug combination treatment groups. (* 






Figure 4.10 Evaluation of GCS-SM/DOX NP effect using ex vivo imaging. (A) Ex 
vivo images of different organs, (B) open chest mice, (C) and the fluorescent 






Figure 4.11 Histology analysis of lung and liver of mice. (H&E staining and 





Outlook for the future development of multifunctional nanocarriers for 
cancer therapy 
There has been a boost in developing nanocarrier-based therapies for 
treating cancer or other diseases during the past decades. In addition of 
selectively accumulating in tumors through EPR effect, nanocarriers enhance the 
bioavailability of poor soluble compounds. In order to fully exploit the technology 
and improve safety in clinical application, we developed two types of nano-
carriers: 1) glycol chitosan based nanomedicine; 2) gold nanoparticles gated 
mesoporous silica nanoparticles.  
We first developed an environment-sensitive peptide delivery system, dual 
secured nano-sting (DSNS), through the combination of a zwitterionic glycol 
chitosan and disulfide bonds. It released drug only if it went through the 
environment that had both acidic and reducing conditions. To further take 
advantage of this electrostatic system, we built the co-delivery system by which 
the suramin and DOX were delivered at the optimized ratio and with high loading 
efficiency in this nano-formulation. Suramin can act as a dual functional agent, 
for which it can act as a crosslinking agent as well as an angiogenesis inhibitor. 
The new nanoparticle was able to improve the median survival time of mice with 




elaborate this combination effect in vivo, it will be beneficial to build an animal 
model where the metastasis process is induced in a different way. Instead of the 
tail vein injection of MDA-MB-231-GFP-Luc cells into nude mice, 4T1-Luc cells 
can be injected through the orthotopic implantation of in Balb/c mice. The 
orthotopic implantation exhibits a higher similarity with human metastasis 
process by controlling the direction of tumor progression from primary tumor to 
lung metastasis, and also makes it possible to investigate the effect of GCS-
SM/DOX NP in inhibiting primary tumor.  
In addition, we fabricated gold nanosphere/mesoporous silica hybrid 
(GoMe) nanocarriers which are suitable for encapsulating both hydrophilic and 
hydrophobic drugs. GoMe can release the encapsulated cargoes in response to 
either NIR irradiation or intracellularly elevated redox potential. DOX@GoMe 
coupled with NIR showed a synergistic effect compared to its components of 
applying either PTT alone or DOX treated cell alone. Furthermore, 64Cu-labeled 
GoMe can successfully detect the spontaneous lung tumors in a urethane-
induced lung cancer mouse model through PET imaging. However, GoMe also 
showed a high accumulation in liver. In order to increase the targeting efficiency 
and completely eradicate cancer cells, we developed the sigma 2 receptors 
targeted GoMe for cancer photothermal therapy and photodynamic therapy. By 
combining PTT and PDT, MBA Pc 4 GoMe efficiently killed UMSCC 22A and A 
2058 cells. In vivo experiment established by subcutaneously injecting UMSCC 
22A cells in nude mice proved that this targeting GoMe combining PTT and PDT 




be beneficial to evaluate the biodistribution of MBA Pc 4 GoMe. We expect a 
higher tumor selectivity of MBA Pc 4 GoMe and lower accumulation in liver after 
i.v injection. In addition, a systemic investigation of the structure–activity 
relationship of MBA and sigma 2 receptor would be valuable.  
Overall, various multifunctional nanocarriers are being developed in my 
PhD research. By infusing the first nano-delivering system with high targeting 
efficacy, the function of diagnosis, higher drug-loading capacity and versatile 
drug-loading flexibility, our newer generation of nanocarriers promises to be more 
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